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Abstract 
 
The parasite Trypanosoma brucei is the causative agent of Human African 
trypanosomiasis and Nagana in cattle and millions of people in sub-Saharan Africa are 
at risk for both health and economic issues since current drugs are inadequate.  
N-linked glycosylation in Trypanosoma bruceidiffers from other eukaryotes and the 
parasite has several essential glycoproteins.Thus, the study of oligosaccharyltransferase 
activities is interesting for potential future drug discoveries. To assess whether 
TbSTT3A is essential in vitro(i.e. in culture), it was replaced by a drug resistance gene 
in the presence of a tetracycline inducible TbSTT3A ectopic copy. Although both 
endogenous TbSTT3A genes were replaced in the TbSTT3 locus, the TbSTT3A 
function was shown to be retained. These results might suggest that the cells have 
rearranged their genome during TbSTT3A replacement, which would imply that the 
tetracycline-inducible ectopic copy could not complement the loss of the endogenous 
TbSTT3A gene, suggesting that it is essential for cell viability in vitro. Additionally, in 
situ tagging of TbSTT3A enabled us to search for potential binding partners by 
performing blue native gel electrophoresis and immunoprecipitation using a Stable 
Isotope Labelling of Amino acids in Cell culture (SILAC) methodology. The results, 
further strengthened by co-immunoprecipitation, suggested that TbSTT3A forms a large 
multimeric complex with TbSTT3B in Trypanosoma brucei. To our knowledge, this is 
the first time two different STT3 enzymes have been reported to associate in an OST 
complex. Furthermore, to investigate why TbSTT3A prefer sequons surrounded by 
acidic amino acids, protein models of the Trypanosoma brucei STT3s were constructed. 
They revealed an intriguing arginine residue at position 397 (that was not found 
inTbSTT3B), which seems to point straight into the active site of TbSTT3A. To further 
xv 
 
elucidate how surrounding acidity affects TbSTT3A glycan transfer, different acceptor 
peptides containing only alanines and a single aspartic acid in various flanking positions 
were fused to a glycosylation reporter protein. Using this reporter, the percentage of 
TbSTT3A glycan transfer was calculated. The results showed that a single aspartic acid 
in any of the two positions immediately adjacent to the asparagine (X-N-X-S/T) 
increased TbSTT3A glycosylation up to 60-70 % compared to 5 % in the alanine 
control. Taken together, it is possible that the arginine in position 397 can interact with 
the aspartic acids immediately adjacent to the asparagine and thus play a major role in 
TbSTT3A and TbSTT3B sequon specificity. 
The findings from these experiments have given a greater understanding of the TbOST 
complex and the specific acceptor peptide selectivity of TbSTT3A and TbSTT3B in 
Trypanosoma brucei.
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1 – Introduction 
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1.1 Human African Trypanosomiasis 
 
Human African trypanosomiasis (HAT), or sleeping sickness, is a vector-borne disease 
caused by the extracellular protozoan parasite Trypanosoma brucei (T. brucei). T. 
brucei is transmitted by the bite of a tsetse fly (Glossina genus) when taking a blood 
meal and the resulting disease in cattle is called nagana. The disease is only spread in 
sub-Saharan Africa, in discrete areas of endemicity within the geographic distribution of 
the tsetse fly. Humans are infected by two parasite sub-speices: Trypanosoma brucei 
rhodesiense and Trypanosoma brucei gambiense(Simarro et al., 2012). T. b. gambiense 
infections are mainly seen in West and Central Africa and cause the chronic form of the 
disease (Balmer et al., 2011; Checchi et al., 2008a, 2008b). T. b. rhodesiense infections, 
on the other hand, are mainly seen in Eastern and Southern Africa and cause an acute 
form of the disease with a more rapid onset and progression. (Balmer et al., 2011; 
Chappuis et al., 2005a; Simarro et al., 2012).Trypanosoma brucei gambiense is 
responsible for 90 to 95 % of all reported cases, with T. b. rhodesiense accountable for 
the remainder (Simarro et al., 2010).Both parasites cause early stage symptoms 
including fever, malaise, anaemia, headache, weight loss and weakness. In this first 
stage, the parasites are limited to the bloodstreamand the lymphatic system (Sternberg, 
2004). In the later stage, the trypanosomes have crossed the blood-brain barrier and 
invaded the central nervous system. The latter, more advanced stage, leads to 
neurological damage, sleep cycle disruption and coma. Both forms of HAT are 
generally lethal if left untreated (MacLean et al., 2012; Wolburg et al., 2012). 
Today, the recorded number of new cases has reduced below 10,000 per year,however 
the prevalence of HAT is predicted to be higher due to under-reporting. Furthermore, 
approximately 70 million people are estimated to be at risk of contracting HAT(Simarro 
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et al., 2011, 2012).The standard field diagnostic tool for HAT is the card agglutination 
trypanosomiasis test (CATT). However, this test has limitations including limited 
sensitivity and specificity and only being T. b. gambiense compatible. Furthermore. it is 
also difficult to distinguishing between infected and cured individuals (Lejon et al., 
2010; Paquet et al., 1992). Determining the stage of the infection is still necessary to 
predict whether the trypanosomes have passed the blood-brain barrier and invaded the 
CNS or not. This is done by lumbar puncture and cerebrospinal fluid examination 
(Chappuis et al., 2005b). 
Many of the drugs that are currently used to treat the disease are old and have severe 
limitations, whilst none of the therapeutic agents are effective against both stages. 
pentamidine and suramin can be used against the first stage of HAT caused by T. b. 
gambiense, while first stage HAT caused by T. b. rhodesiense can only be treated by 
suramin (Bouteille et al., 2003).However, these compounds do not penetrate the blood-
brain barrier. The drug of choice forlate stage T. b. gambiense is mainly nifurtimox-
eflornithine combination therapy (NECT), whereas melasoprol is only used for late 
stage T. b. rhodesiense infections (Kennedy, 2012; Priotto et al., 2009; Simarro et al., 
2011).Some of the aforementioned therapeutic agentscause severeside-effects, including 
melasoprolwhich can cause lethal encephalopathy in 5-10% of the cases. (Fairlamb, 
2003; Renslo and McKerrow, 2006).The drugs used for treating HAT are also 
expensive and difficult to administer in rural areas because of the need for sterile 
instruments and trained personal (Simarro et al., 2008). Therefore, new, affordable and 
safer drugs that are effective against both stages of infections and both sub-species, and 
that are easier to administrate, are urgently needed. 
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1.2 Trypanosoma brucei life cycle and cell biology 
 
T. brucei is a unicellular parasite that belongs to the kinetoplastida order, family 
trypanosomatidae. The parasite has a complex life cycle that allows it to alternate 
between the insect vector and the mammalian host (Figure 1.1). This requires the 
parasite to present different morphologies and surface coatsto survive in the different 
environments (Fenn and Matthews, 2007). Bloodstream form parasites can be ingested 
by the tsetse fly during a blood meal, and within the fly, the parasites differentiate into 
the proliferative procyclic form to be able to colonize the insect mid gut. Subsequently, 
the procyclic parasites migrate to the insect salivary gland, where they differentiate into 
the epimastigote form. The proliferative epimastigotesthen differentiate into the 
infective metacyclic trypomastigotes, which are ready to be injected into another 
mammalian host during a new blood meal (Van Den Abbeele et al., 1999; Sbicego et 
al., 1999; Sharma et al., 2009). When this occurs, the metacyclic parasites are injected 
into the bloodstream of the mammalian host, where they differentiate into long and 
slender bloodstream form trypomastigotes, dividing rapidly and  infecting other sites. 
However, the bloodstream cell population is phleomorphic, and when the cell 
concentration increases more cells develop into the stumpy form. The stumpy form is 
non-proliferative and ready to be taken up by the insect via a new blood meal and 
subsequently differentiate to procyclic form, thereby continuing the life cycle (Fenn and 
Matthews, 2007; Sbicego et al., 1999). 
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The bloodstream form of the parasite is covered by a dense coat of variant surface 
glycoproteins (VSG) which allows small molecules to diffuse to the plasma membrane, 
but prevents macromolecules from reaching it, e.g. the parasites are protected from 
complement mediated lysis.(Cross, 1975a; Fenn and Matthews, 2007). The surface coat 
changes when stumpy bloodstream parasites differentiate into the procyclic form, which 
has procyclin glycoproteins as the most abundant surface molecule (Sbicego et al., 
1999). The epimastigote form, on the other hand, expresses a surface coat protein called 
brucei alanine rich protein (BARP) (Fenn and Matthews, 2007). 
The experiments in this thesis have solely been done using the bloodstream form T. 
brucei and therefore the cell biology will be focussed on this specific stage of the life 
cycle. 
Figure 1.1.Life cycle of T. brucei. Image adapted from Centre for Disease Control 
(http://www.cdc.gov/parasites/sleepingsickness/biology.html) 
6 
 
The cell surface of bloodstream form Trypanosoma brucei is covered with an estimated 
5 million homodimers of VSG glycoproteins. The parasite has several hundred genes, 
some of which are pseudogenes, coding for these VSG dimers, allowing the parasite to 
switch between immunologically distinct VSG surface coats. This antigenic variation is 
the reason why the host immune system cannot control parasite growth and why the 
parasitemia occurs in waves (Cross, 1975a, 1979; Ferguson et al., 1988; Horn and 
Cross, 1997). 
T. brucei is a flagellated organism, where the main function of the flagellum is motility, 
which has been shown to be essential for the parasite viability(Broadhead et al., 2006). 
The flagellum exits the cell in the flagella pocket, which is the sole known site for 
endocytosis and exocytosis even though it only represents approximately 5 % of the 
plasma membrane (Landfear and Ignatushchenko, 2001). 
T. brucei parasite cells have an organelle called the glycosome, which isthe 
trypanosome equivalent of the peroxisome. However, unlike other eukaryotes, most of 
the steps of glycolysis occur inside this organelle (Michels et al., 2006; Opperdoes and 
Borst, 1977). Several biosynthetic pathways have been localised in the glycosome, 
including, β-oxidation of fatty acids (which is commonly found in peroxomes) the 
pentose-phosphate pathway, purine salvage and pyrimidine biosynthesis (Cáceres et al., 
2010; Michels et al., 2006; Zomer et al., 1995).What is particularly relevant to work in 
this thesis, is that most, if not all, of the sugar nucleotide biosynthesis is localised to the 
glycosome. These activated sugar nucleotides play an important role in N-glycan 
assembly (Bandini et al., 2012; Kuettel et al., 2012; Mariño et al., 2010; Roper et al., 
2005; Stokes et al., 2008; Turnock and Ferguson, 2007). 
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1.3 N-linked glycobiology 
 
Asparagine (N)-linked glycosylation of proteins is a vital and extensive post-
translational modification catalysed by the oligosaccharyltransferase (OST). 
Glycosyaltion results in a covalent bond between a largepreassembled glycan and the 
asparagine residue in a specific sequon, N-X-S/T (variations of the sequon occurs, see 
section 1.3.2), found in nascent proteins. For membrane and secretory proteins in 
eukaryotic organisms, it is the mostfrequent protein modification. N-linked glycans can 
serve numerous functions including aiding the folding process of proteins in the ER 
(Helenius, 1994). The hydrophilic nature of the covalently attached glycan alters the 
biophysical properties of the nascent protein and can affect the conformation of the 
unfolded polypeptide chain and it can thereby influence protein folding (Wormald and 
Dwek, 1999). Furthermore, glycans can mediate interactions of the cell or the organism 
with its environment (Sharon and Lis, 1995). 
The high conservation of the process across all domains of life has made it feasible to 
identify the major principles of the pathway of N-linked glycosylation (Lizak et al., 
2011; Wacker et al., 2006).  
 
1.3.1 Glycan assembly in eukaryotes 
 
In most eukaryotes, the oligosaccharide assembly starts on an isoprenoid lipid at the 
cytoplasmic side of the ER membrane. The isoprenoid lipid, the dolichol molecule, 
carries the oligosaccharide in the membrane of the ER, making it a vital part of the N-
linked glycosylation pathway (Lehrman, 1991; Schenk et al., 2001). The dolichol 
molecule is synthesised from farnesylpyrophosphate by the sequential addition of C5 
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isoprenoid units, catalysed by the cis-prenyltransferase. The length of the dolichol 
carrier is species-dependent and the trypanosamatid version is unusually short, 
containing 11-12isoprene units (Figure 1.2) (Low et al., 1991; Swiezewska and 
Danikiewicz, 2005; Welti, 2013).  
 
 
 
Dolichol is subsequently phosphorylated by the Dol kinase (DOLK) and is then ready to 
serve as a carrier for the precursor oligosaccharide assembly (Heller et al., 1992). The 
start of oligosaccharide precursor assembly is located to the cytoplasmic side of the ER 
membrane and three different nucleotide-activated sugar donors are needed to 
synthesise the Man5GlcNAc2 intermediate oligosaccharide; UDP-N-acetylglucosamine 
(UDP-GlcNAc), GDP-mannose (GDP-Man) and UDP-glucose (UDP-Glc) (Burda and 
Aebi, 1999; Huffaker and Robbins, 1983).These sugar nucleotides act as substrates for 
glycosylation reactions, andin higher eukaryotesthey are synthesised in the cytoplasm 
and subsequently used on the ER surface and in the lumen, as well as the Golgi 
apparatus. (Varki A, Esko JD, 2009).A number of glycosyltransferases are involved in 
these sugar donor transfers and ALG7 and ALG13/14 catalyse the transferof the first 
two GlcNAc sugars from UDP-GlcNAc to the Dol-P molecule. In the first of these two 
reactions, GlcNAc is transferred together with a phosphategroup, generating dolichol-
PP-GlcNAc. Following the addition of the second GlcNAc, five Man sugars are 
transferred to the growing lipid-linked oligosaccharide (LLO). These reactions are 
Figure 1.2.The dolichol molecule found involved in oligosaccharide assembly in T. 
brucei. 
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catalysed by ALG1, ALG2 and ALG11, and use GDP-Man as their substrate(Cipollo et 
al., 2001; Couto et al., 1984; O’Reilly et al., 2006). The Man5GlcNAc2-PP-Dol 
molecule is then flipped to face the lumenal side of the ER. Some evidence suggested 
that the Rft1 protein in yeast was involved in translocation of the LLO intermediate, 
however, a subsequent in vitro analysis challenged these results (Frank et al., 2008; 
Helenius and Aebi, 2002; Ng et al., 2000; Rush et al., 2009).Work carried out in the T. 
brucei procyclic form has suggested that Rft1 influences assembly of the LLO 
precursor, although not by catalysing the translocation through the ER membrane (Jelk 
et al., 2013). On the lumenal side of the ER, assembly continues by the addition of four 
mannose sugars to form the B and C branches (Figure 1.3). These reactions are 
catalysed by ALG3, ALG9 and ALG12(Aebi et al., 1996; Burda et al., 1999; Frank and 
Aebi, 2005). In these steps, Dol-P also plays a crucial role as a carrier for Man and Glc 
which are transferred from GDP-Man and UDP-Glc to the Dol-P molecule in order to 
transfer these activated sugar nucleotides to the assembling precursor glycan on the 
lumenal side of the ER membrane (Heesen et al., 1994; Orlean et al., 1988). How the 
dolichol-Pis able to flip across the membrane with bound Man or Glc is yet to be 
discovered.In most eukaryotes, the final step of lipid-linked oligosaccharide assembly is 
the addition of three glucose molecules to the A branch from Dolichol-P-Glc by AlG6, 
ALG8 and ALG10 (Burda and Aebi, 1998; Reiss et al., 1996; Stagljar et al., 1994). 
Thus, the precursor oligosaccharide in most eukaryotes is Glc3Man9GlcNAc2 (Figure 
1.4). 
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Figure 1.3.(previous page) Schematic view of lipid-linked oligosaccharide assembly 
in T. brucei. The first GlcNAc is transferred as GlcNAc-P from UDP-GlcNAc in a 
reaction catalysed by ALG7. In the second reaction, GlcNAc is transferred from 
UPD-GlcNAc to the growing LLO. The remaining five reactions on the cytoplasmic 
side of the ER are the additions of Man residues from GPD-Man in reactions 
catalysed by ALG1, ALG2 and ALG11. The Man5GlcNAc2-PP-Dol molecule is then 
flipped to the lumenal side of the ER, in a reaction that is suggested to involve Rft1. 
On the lumenal side, Man5GlcNAc2-PP-Dol is extended to Man9GlcNAc2-PP-Dol by 
the addition of four mannoses from Man-P-Dol to the B and C branches (different 
branches highlighted for Man9GlcNAc2), catalysed by ALG3, ALG9 and ALG12. 
The Dol-P-Man donor is made by the transfer of Man from GDP-Man to Dol-P by 
DPMS1 on the cytoplasmic face of the ER and is translocated into the lumen of the 
ER. Subsequently, OSTs transfer Man5GlcNAc2 and Man9GlcNAc2 to N-X-S/T 
sequons in nascent proteins, which aids protein folding. The oligosaccharides can be 
processed into different types of glycans in the ER and Golgi. In most eukaryotes, 
the final step of lipid-linked oligosaccharide assembly is the addition of three 
glucose molecules to the A branch from Dolichol-P-Glc by ALG6, ALG8 and 
ALG10. 
12 
 
 
 
While most of the ALG genes have identifiable homologues in T. brucei, only two have 
been experimentally characterised; TbALG3 and TbALG12 (Jones et al., 2005; Manthri 
et al., 2008; Samuelson et al., 2005). Notably, dolichol-P-Glc dependent glucosylation 
reactions do not occur in the parasite and Man9GlcNAc2-PP-Dol is the largest precursor 
oligosaccharide made by T. brucei (Figure 1.3) (Acosta-Serrano et al., 2004; Jones et 
al., 2005). 
The dolichol carrier can be regenerated following glycosylation which means that the 
levels of the dolichol molecule on the cytoplasmic side of the ER are not solely 
dependent on the de novo biosynthesis but also the recycling of the molecule (van 
Berkel et al., 1999). 
 
 
 
 
 
 
Figure 1.4.Precursor oligosaccharide for most eukaryotes, Glc3Man9GlcNAc2. 
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1.3.2 Acceptor peptide sequon 
 
When nascent proteins enter the ER lumen, they are in an extended and flexible 
conformation which is preferred by OST for efficient transfer of the precursor 
oligosaccharides. Subsequently, N-glycosylation occurs approximately 30 residues from 
where the ribosomes meets the translocon on the ER surface (Varki et al., 1999). A later 
study refined the knowledge to show that glycosylation occur approximately 65 residues 
from the peptidyltransferase centre in the ribosome (Kowarik et al., 2002).However, N-
glycans arenot transferred to everypotential glycosylation sequon and some sites are 
sub-stoichiometrically occupied (Jenkins et al., 1996). The consensus of the field has 
been that up to approximately 60 % of all proteins are N-glycosylated, but recent data 
challenge that view, stating that less than one fifth of all proteins actually receive 
glycans from OSTs (Apweiler et al., 1999; Khoury et al., 2011). Furthermore, it has 
been estimated that approximately 70 % of the sequons on mouse glycoproteins are 
occupied (Zielinska et al., 2010).  
Even though the N-X-S/T sequon is the most abundant in N-glycan transfer, there are 
exceptions. Bacterial OST transfers lipid-linked oligosaccharides to D/E-X-N-X-S/T 
sequons, thus exhibiting a more stringent specificity for acceptor sequons than seen in 
eukaryotes. Additionally, 1 % of the glycosylation sequons that are efficiently used in 
the mouse glycoproteome are N-X-C sites (Chen et al., 2007; Wacker et al., 2006; 
Zielinska et al., 2012). Also, valine, leucine or asparagine can switch with the serine in 
the sequon of a cell surface protein in Halobacterium halobium and an N-S-G sequon 
has been shown to accept an oligosaccharide in Campylobacter lari(Schwarz et al., 
2011; Zeitler et al., 1998). Furthermore, detailed analysis has suggested that threonine is 
found more often than serine in the +2 position of the N-X-S/T sequon and that small 
hydrophobic amino acids are preferred at the X position (Zielinska et al., 2012). Lastly, 
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it has been proposed that N-glycosylation sequons are mostly found in potential loops 
and turns of proteins (Petrescu et al., 2004). 
 
1.3.3 Oligosaccharyltransferase – structure and function 
 
Ina crucial reaction of the N-linked glycosylation pathway, OST, a multimeric complex 
in mosteukaryotes, transfers a preassembled precursor oligosaccharide to the asparagine 
residues within the sequons of nascent proteins. Since OSTs glycosylate polypeptides 
that enter the ER, it was not surprising that data provided evidence that parts of the OST 
are associated with the translocon (Shibatani et al., 2005). 
Human OST is a heptameric membrane complex (Figure 1.5) whereas yeast OST, the 
most extensively investigated, consists of eight subunits: Ost1 (ribophorin I), Ost2 
(DAD1), Ost3 or Ost6 (N33/Tusc3 or IAP/MagT1), Ost4 (Ost4), Ost5, Wbp1 (OST48), 
Swp1 (ribophorin II) and STT3 (STT3A/STT3B) (human subunits in brackets). Of these 
subunit proteins, fiveare essential for yeast viability: Ost1 (ribophorin I), Ost2 (DAD1), 
Wbp1 (OST48), Swp1 (ribophorin II) and STT3 (STT3A/STT3B) (Kelleher and 
Gilmore, 2006; Li et al., 2008; Mohorko et al., 2011). 
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Ribophorin I, ribophorin II and OST48 were the first protein subunits of the mammalian 
OST complex to be identified (Silberstein et al., 1992). Ribophorin I has one predicted 
transmembrane helix; a small C-terminal cytosolic domain and a large, luminal domain. 
Itis an abundant rough ER proteinthat is approximatelystoichiometric to membrane-
bound ribosomes (Kreibich et al., 1978a, 1978b; Marcantonio et al., 1984). 
Additionally, ribophorin I has been shown to enhancethe N-glycosylation of specific 
type I and type II membrane proteins, possibly by binding poorly glycosylated sequons, 
thereby giving these peptides a greater chanceto be acted upon by the catalytic STT3 
subunits of the OST complex. (Wilson and High, 2007). 
Ribophorin II is also found in approximately stoichiometric amounts with ribophorin I 
and membrane-bound ribosomes(Kreibich et al., 1978a, 1978b; Marcantonio et al., 
1984). It is highly conserved in mammals and sequence analysis suggests it has a large 
N-terminal lumenal domain, three predicted α-helices in a transmembrane domain and a 
small C-terminal cytosolic segment (Crimaudo et al., 1987). Downregulation of 
ribophorin II in human breast cancer cells has been shown to lead tohypoglycosylation 
of selected membrane proteins(Honma et al., 2008). 
Figure 1.5.Subunits of human OST (Mohoker et al, 2014). 
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Ost48 was detected together with the two ribophorins (Silberstein et al., 1992). Human 
Ost48 has a large N-terminal lumenal domain, followed by a single transmembrane span 
and a short C-terminal cytoplasmic domain consisting of nine amino acids. The C-
terminus of canine OST48 has been shown to interact with DAD1, whereas the N-
terminal lumenal domain has been reported to interact with ribophorin I in yeast. In fact, 
Ost48 seems to act as a link between ribophorin I and ribophorin II by interacting with 
the lumenal domains of the ribophorins, which have not been reported to interact 
directly (Fu et al., 1997). Additionally, Wbp1 in yeast has been suggested to bind the 
LLO substrate, but convincing experimental evidence of this notion has not been 
presented (Pathak et al., 1995). 
DAD1 is the most conserved OST subunit and the human protein is highly similar to the 
mouse, rat and hamster homologues. The protein (12 kDa) is the second smallest 
subunit of the OST complex, with both termini on the cytosolic side of the ER 
membrane and two transmembrane helices in the centre. As mentioned above, the 
DAD1 C-terminal domain has been reported to interact with OST48 and, moreover, the 
protein has been reported to be in tight association with the active OST complex (Fu et 
al., 1997; Kelleher and Gilmore, 1997). 
Ost4 is the smallest protein subunit in both mammalian and yeast OST complex, 
consisting of only 37 residues including a single transmembrane helix (Kelleher and 
Gilmore, 2006). Although highly conserved, and despite structural data for human Ost4 
(Gayen and Kang, 2011), not much was known about the function of mammalian OST4 
until a recent study (Dumax-Vorzet et al., 2013). It was shown that mammalian OST4 
was important for stability of the OST complex and knockdown resulted in a mild 
defect in the N-glycosylation of an endogenous HeLa glycoprotein. Also, in yeast, point 
mutations in the transmembrane part of OST4p disrupt the OST4, OST3, and STT3 
interaction and cause growth defects (Kim et al., 2000, 2003). 
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STT3 is the largest protein subunit of the OST complex (Spirig et al., 1997). About 10 
years ago, data providing evidence about the catalytic role of STT3 in OST complexes 
was presented (Kelleher et al., 2003; Nilsson et al., 2003). The N-terminal regions of 
STT3 proteins contain a hydrophobic membrane-anchor domain of 11 or 13 predicted 
transmembrane helices followed by a soluble, catalytic C-terminal domain which 
extends into the ER lumen(Kelleher and Gilmore, 2006). In mammals, two isoforms of 
STT3 (STT3A and STT3B) are encoded in the genome.However, the two proteinsare 
not incorporated into the same complex, insteadtwo different OSTs, with either STT3A 
or STT3B, are expressed (Kelleher et al., 2003). The two OST complexes are co-
expressed in several tissues, but they vary inexpression levels. Human STT3A and 
STT3B proteins share 59% amino acid sequence identity and STT3B is slightly larger 
than STT3A(Kelleher et al., 2003). Furthermore, OST complexes with STT3B as the 
catalytic subunit have been reported to be more active than the STT3A complex form 
(Kelleher et al., 2003; Ruiz-Canada et al., 2009). Additionally, STT3A and STT3B have 
been shown to have specific acceptor substrate selectivity. In 2007, Wilson and High 
analysed the glycosylation state of specific membrane proteins subsequent to siRNA-
mediated STT3A/STT3B knockdown in HeLa cells. When depleting STT3A, loss of 
both OST isoforms was seen, accompanied by the abolition of glycosylation. In 
contrast, depletion of STT3B did not abolish glycosylation completely, instead 
hypoglycosylation was seen on certain membrane proteins(Wilson and High, 2007). 
Although a more recent study presented contradicting data, suggesting that depletion of 
STT3A or STT3B increases the expression level of the non-affected protein, the same 
study provided insight to the order of glycosylation of STT3A and STT3B(Ruiz-Canada 
et al., 2009). OST complexes containing STT3A were shown to catalyse co-
translational transfer of the precursor oligosaccharide, whereas STT3B complexes 
catalysed post-translational glycosylation of remaining sequons (Ruiz-Canada et al., 
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2009). This study also suggested distinct enzymatic properties in that STT3B complexes 
(unlike the STT3A equivalent) could mediate glycosylation of asequon found adjacent 
to the C-terminus of a secreted protein(Ruiz-Canada et al., 2009). Lastly, a recent study 
demonstrated that N-X-S sequons withpositively charged, small hydrophobic andpolar 
side chains in the X position are efficiently co-translationally glycosylated by STT3A 
OST. However bulky, hydrophobic or negatively charged amino acids in the X position 
were frequently skipped during co-translational glycosylation by TbSTT3A OST 
(Malaby and Kobertz, 2014). 
The two mammalian proteins ,MagT1/IAP and TUSC3/N33, were initially suggested to 
be homologous to the yeast Ost3 and Ost6 proteins(Kelleher et al., 2003; MacGrogan et 
al., 1996). Despite low sequence identity (20%) between TUSC3 or MagT1 and yeast 
Ost3/Ost6, the four proteins share a lumenal thioredoxin domain (Fetrow et al., 2001; 
Kelleher and Gilmore, 2006; Mohorko et al., 2014). Furthermore, mutation of the 
CXXC motifs in Ost3 or Ost6 decreases glycan occupancy on specific sequons in yeast 
glycoproteins (Schulz et al., 2009). Recently, it has been proposed that MagT1/IAP 
exclusively assemble with the STT3B OST complex and that it can enable glycosylation 
of sequons that were not glycosylated by the STT3A complex and that are close to 
cysteine amino acids. This is proposed to be achieved by establishing a transient 
disulfide bridge between MagT1 and the glycoprotein substrate and this mechanism 
helps reduce the competition between disulfide bond formation and N-glycosylation 
(Cherepanova et al., 2014; Mohorko et al., 2014). 
The most recent discovered subunits that associate with the OST complex are KCP2 and 
DC2. DC2 shows weak homology to the C-terminal half of Ost3 and Ost6 in yeast. 
However, no domain homology was found for KCP2. A recent study revealed that 
KCP2 is important for stability of the STT3A-containing OST complex and that it plays 
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a part in substrate selectivity by this complex(Roboti and High, 2012a; Shibatani et al., 
2005). 
As previously mentioned, N-linked glycosylation is also found in bacteria and archaea, 
however, OSTs in these organisms are not protein heterologous complexes. Instead, 
they are composed by single proteins that are homologues to STT3, called PglB in 
bacteria and AglB in archaea (Chaban et al., 2006; Dell et al., 2010; Guan et al., 2010; 
Jervis et al., 2010; Kelleher et al., 2007; Kelly et al., 2009; Schwarz et al., 2011). 
Archaea displays a great diversity in glycosylation pathways, by using many different 
sugar building blocks and requiring a wider variety of donor substrates than found in 
eukaryotes. Bacteria exhibit a more limited N-glycan range than archaea, and N-linked 
glycosylation is restricted to a relatively small number of species (Guan et al., 2010; 
Kelleher et al., 2007). The first complete OST crystal structure that was solved was 
from the bacteria Campylobacter lari, giving many insights about the architecture of 
this class of enzymes together with possible modes of mechanisms (Lizak et al., 2011). 
One long loop (EL5), which connects two transmembrane helices, was reported to be 
only partially ordered, with 25 residues being disordered in the electron density map. 
Based on the proposed mobility of the EL5 loop, a three state mechanism was proposed 
for PglB catalysed glycosylation (Figure 1.6). Upon binding the acceptor peptide, the C-
terminal end of EL5 is ordered and pins the sequon-containing peptide to the 
periplasmic domain, thus restricting the mobility of the peptide. Once the LLO is bound 
by PglB, a nucleophilic attack of the activated amide nitrogen occurs and the nascent 
protein becomes glycosylated. Subsequently, the attached oligosaccharideis closely 
pressed against PglB, causing steric tension which will initiate disengagement of EL5 
and allow release of the glycosylated protein. However, there are no data as to which 
event occurs first, the binding of the acceptor peptide or the binding of the LLO (Lizak 
et al., 2011). 
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Figure 1.6.Proposed mechanism for N-glycosylation in C. lari. 1) In the first stage, 
the EL5 loop is going from being disordered, generating a possibility to bind the 
acceptor protein, to having the C-terminal of the EL5 loop ordered and bound to the 
acceptor peptide. Thus, the C-terminal part of the EL5 loop pins the nascent protein 
against the periplasmic domain, hence limiting the mobility of the peptide. 2) In the 
second stage, the LLO binds the other cleft of the C. lari OST, accommodating 
proximity of the two substrates to generate glycosylation. 3) In the third and last 
step, the loop is disordered again, enabling the release of glycosylated sequon and 
lipid-pyrophosphate (PP)(Lizak et al., 2011) 
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A more recent study supported the view of the EL5 loop being part of the binding 
process of the acceptor peptide, but the study also elaborated the role of the N-terminus 
of the loop (Lizak et al., 2014). The first 25 residues of the EL5 loop were not visible in 
the electron density map, however, a conserved tyr/phe motif was shown to be essential 
for catalysing the glycan transfer. The motif is believed to interact with the LLO, 
possibly by forcing the reducing end of the sugar into a preferred, reactive conformation 
(Lizak et al., 2014). 
It is important to note that alternative N-glycosylation pathways have been discovered 
in a few bacteria (Choi et al., 2010; Grass et al., 2003, 2010; Gross et al., 2008). These 
reactions take place in the cytoplasm, where monosaccharides from activated sugar 
donors are transferred to an asparagine in the same sequon used by OST, N-X-S/T. The 
enzyme catalysing this transfer, N-glycosyltransferase (NGT), does not belong to the 
same structural class of enzyme as OST, implying that the same sequon specificity has 
emerged twice in evolution and has resulted in parallel enzymatic activity (Choi et al., 
2010; Grass et al., 2003, 2010; Gross et al., 2008). 
 
1.4 N-linked glycosylation and oligosaccharyltransferase activities in T. brucei 
 
1.4.1 Glycoproteins in T. brucei 
 
T. brucei has several known glycoproteins (VSG, ISG65 and ISG75, Fla1, the 
transferrin receptor, p67, tGLP1, GPIdeAc and TbMBAP1)and many of them are 
essential for cell survival (Cross, 1975a; Engstler et al., 2005; Güther et al., 2003; 
Kelley et al., 1999; Lingnau et al., 1999; Mehlert, 1998; Mehlert et al., 2012; Nozaki, 
1996; Steverding et al., 1994; Wooten et al., 1990; Ziegelbauer and Overath, 1992). The 
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different types of oligosaccharides that can be found on T. brucei proteins are 
summarised in Figure 1.7.  
 
 
 
The VSGs form a densely packed layer of dimers on the cell surface which are anchored 
in the membrane byglycosylphosphatidylinositol (GPI)(Ferguson et al., 1988). The N-
linked glycan structure of a fewvariants of T.brucei VSGs have been solved,showing 
that each VSG variant contains one, two, or three N-linked oligosaccharides per 
monomer(Mehlert et al., 2002, 2010; Strang et al., 1993; Wooten et al., 1990; Zamze et 
al., 1991). VSG221 is found on the Lister 427 T. brucei strain used for the work carried 
out in this thesis and this VSG variant contains two N-glycosylation sites, one at 
Asn263 and one at Asn428, occupied by different types of oligosaccharides. The 
oligosaccharides covalently attached to the asparagine in position 263, consist of small 
biantennary complex and paucimannose oligosaccharides.The asparagine at position 
428 is occupied mostly by oligomannose glycans.(Zamze et al., 1991). The transferrin 
receptor is another glycoprotein in T. brucei and it is localised in the flagellar pocket 
where it is anchored to the membrane via a GPI(Steverding et al., 1994). The receptor is 
a heterodimer consisting of the expression site associated gene 6 and 7 (ESAG6 and 
Figure 1.7.Typical samples of the different types of oligosaccharides found bound to 
the asparagine in the N-X-S/T sequon of T.bruceiglycoproteins. 
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ESAG7) and has recently been reported to have eight N-glycosylation sequons occupied 
with either oligomannose or paucimannose glycans (Mehlert et al., 2012). 
 
1.4.2 Oligosaccharyltransferase in T. brucei 
 
Just like in bacteria and archaea, OST in T. brucei is suggested to comprise of a single 
protein, the catalytic subunit STT3. No other OST subunit homologues were found in in 
the T. bruceigenome, however, three STT3 genes (TbSTT3A, TbSTT3B and TbSTT3C) 
were found in a tandem array on the fifth chromosome (Figure 1.8) (Berriman, 2005; 
Kelleher and Gilmore, 2006). It is possible that T. brucei diversified the single subunit 
OST by gene duplication, in a similar manner to the related kinetoplastid parasite 
Leishmania major(Hese et al., 2009; Nasab et al., 2008). 
 
 
 
The encoded protein sequences of the three genes are highly conserved, with TbSTT3B 
and TbSTT3C showing 95 % identity, whereas TbSTT3A share 79 % identity with them 
both. The three genes are found in a highly repetitive segment of the genome and are 
surrounded by identical untranslated regions (UTRs), highlighted in red and pink in 
Figure 1.8. Both TbSTT3A and TbSTT3B were shown to be expressed at the mRNA 
Figure 1.8.STT3 locus in T. brucei.TbSTT3A shares 79 % sequence identity with 
TbSTT3B and TbSTT3C, whereas TbSTT3B and TbSTT3C are more closely related 
with 95 % sequence identity. There are identical UTRs surrounding the three genes, 
highlighted in pink and red. 
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level in the life cycle stages we culture in the laboratory (bloodstream form and 
procyclic form) and a recent quantitative proteomics study showed that both are more 
highly expressed at the protein level in bloodstream form parasites, 8-fold for TbSTT3A 
and 1.5-fold for TbSTT3B. TbSTT3C, on the other hand, were not detected at the 
mRNA or protein level and has been suggested to possibly play a role in different life 
stages (Izquierdo et al., 2009a; Urbaniak et al., 2013).  
Already in 1988, Bangs and colleagues suggested selective mechanisms for 
glycosylation in T. brucei based on the two specific types of glycan found bound to 
certain sequons on a VSG molecule (Bangs et al., 1988). This assumption has later been 
supported by different studies and Ferguson and colleagues have provided data about 
LLO specificity for TbSTT3A and TbSTT3B (Izquierdo et al., 2009a, 2012; Jones et al., 
2005; Manthri et al., 2008). The biantennary Man5GlcNAc2 oligosaccharide is 
recognised and transferred by TbSTT3A whereas the triantennary Man9GlcNAc2 
oligosaccharide is the preferred oligosaccharide choice of TbSTT3B (Figure 1.9 and 
1.10). Having two distinct precursor oligosaccharides, transferred by two different 
OSTs, is unique for T. brucei. Mammalian and yeast OST complexes are selective for 
the oligosaccharide end product Glc3Man9GlcNAc2 whilst protists and fungi exhibit 
either little specificity for the donor LLO structure or are selective to the end LLO 
product (Kelleher et al., 2007; Samuelson et al., 2005). In T. brucei, the Man5GlcNAc2-
PP-Dol molecule is the most abundant lipid-linked oligosaccharide in both bloodstream 
and procyclic life stages. Studies have shown that if TbSTT3A is depleted, TbSTT3B is 
able to transfer trianntennary Man9GlcNAc2 oligosaccharides to some of the sequons 
normally acted upon by TbSTT3A. However, with TbSTT3A absent, significant 
hypoglycosylation occurs. When TbSTT3B is depleted, TbSTT3A is barely able to 
glycosylate sequons normally acted upon by TbSTT3B and if it does, it exclusively 
transfers Man5GlcNAc2. Therefore, similar to TbSTT3B depletion, loss of TbSTT3A 
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also leads to hypoglycosylation in T. brucei(Izquierdo et al., 2009a). Additionally, a 
more recent study showed that TbSTT3A could transfer Man7GlcNAc2with 
approximately the same efficiency as Man5GlcNAc2 whereas, although TbSTT3B could 
use Man7GlcNAc2with approximately the same efficiency as Man5GlcNAc2, both 
donors were much less efficient than the natural oligosaccharide Man9GlcNAc2. Hence, 
it was suggested that TbSTT3A transfer is reliant on the LLO not having a C-branch, 
whereas TbSTT3B seems to require the C-branch for efficient LLO transfer (Izquierdo 
et al., 2012) (Figure 1.9). 
 
 
 
The related kinetoplastid parasites Leishmania majorand Trypanosoma cruzi have also 
been reported to only encode the catalytic STT3 subunit, but similar to T.brucei, 
Leishmania major have several copies of this gene and probably express STT3 enzymes 
Figure 1.9.Structures of the three oligosaccharides Man9GlcNAc2, Man7GlcNAc2 
and Man5GlcNAc2. The A/B/C-branches are highlighted in Man9GlcNAc2. 
TbSTT3A recognises Man7GlcNAc2 equally well as the native donor Man5GlcNAc2, 
but cannot bind and/or transfer the triantennary Man9GlcNAc2. TbSTT3B can 
recognise and transfer both Man7GlcNAc2 and Man5GlcNAc2, though significantly 
less efficient than Man9GlcNAc2. Therefore TbSTT3B prefers oligosaccharides with 
the C-branch, while TbSTT3A glycan transfer is inhibited by the same (Izquierdo et 
al., 2012).  
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with distinct but overlapping peptide substrate specificities. Some of the single subunit 
OSTs from these parasites have been shown to complement STT3 deletion in yeast 
(Castro et al., 2006; Nasab et al., 2008). Similarly, TbSTT3B and TbSTT3C were able 
to support cell viability in yeast following depletion of the endogenous STT3. 
Interestingly, TbSTT3A could not (Izquierdo et al., 2012). 
When analysing the acceptor peptide specificity of TbSTT3A and TbSTT3B in 
bloodstream form parasites, overlapping but distinct selectivity was observed (Izquierdo 
et al., 2009a). By examining the sequons and surrounding peptide sequences 
(XXXXXNXS/TXXXXX) where the attached glycan type (biantennary transferred by 
TbSTT3A or triantennary transferred by TbSTT3B) were known, a pattern for 
TbSTT3A catalysed transfer was seen. These sequons were often surrounded by acidic 
amino acids and thus the sequon peptide had a relatively low pI value. However, 
TbSTT3B, which catalyses post-translational oligosaccharide transfer, was shown to 
have no specific preference concerning the pI value of the sequon-flanking residues. 
Instead, TbSTT3B, having a broad sequon peptide specificity, was proposed to 
glycosylate sequons that had been overlooked by TbSTT3A (Figure 1.10). This distinct 
but overlapping dual glycosylation has been suggested to produce a high efficiency of 
oligosaccharide transfer in T. brucei(Izquierdo et al., 2009a). Furthermore, the acceptor 
peptide specificity of TbSTT3C was tested in a yeast model, highlighting a tendency to 
glycosylate sequons in an acidic environment, similar to TbSTT3A (Izquierdo et al., 
2009a).  
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1.4.3 N-glycan processing in T. brucei 
 
Oligosaccharide processing in T. brucei occurs both in the ER and in the Golgi 
apparatus. On the lumenal side of the ER, proteins like UDP-Glc:glycoprotein 
glucosyltransferase (UGGT), α-glucosidase II (GII) and calreticulin act upon the glycan 
in order to aid folding of nascent proteins (Izquierdo et al., 2009b). Furthermore, many 
mature glycoproteins in the bloodstream form are equipped with 
complex/paucimannoseand/or oligomannose oligosaccharides, for example (as 
aforementioned), the complex and paucimannose glycans found attached to the 
asparagine at position 263 of VSG221, the paucimannose glycans attached to the 
asparagine at position 94 on the ESAG6 monomer of the transferrin receptor and the 
oligomannose glycans found at position 10 and 344 on the same monomer of the 
receptor and on position 428 of VSG221 (Jones et al., 2005; Mehlert et al., 2012; Zamze 
et al., 1991).  
The two precursor oligosaccharides used in T. brucei, Man5GlcNAc2 and 
Man9GlcNAc2, can only be processed into specific types of glycans. The biantennary 
Man5GlcNAc2 is the only route to complex or paucimannose oligosaccharides, whereas 
Man9GlcNAc2 will only be processed into oligomannose glycans. Presumably, these 
separate routes have evolved from T. brucei lacking a Golgi α-mannosidase II gene, 
such that the oligomannose type of glycan can only be processed as far as triantennary 
Man5GlcNAc2. Thus, the massive poly-N-acetyllactosamine structures that have been 
reported in the bloodstream form of the parasite, originates from TbSTT3A transfer of 
the biantennary Man5GlcNAc2(Atrih et al., 2005; Manthri et al., 2008). 
The steps to produce these complex glycans occur in the Golgi and are catalysed by 
mannosidase and glycosyltransferases, and recently two glycosyltransferases, TbGT8 
and TbGT11, were found to be involved in the construction of complex glycans in both 
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bloodstream (TbGT8 and TbGT11) and procyclic form (TbGT8) (Damerow et al., 2014; 
Nakanishi et al., 2014). 
Following RNAi induced knockdown of TbSTT3A and TbSTT3B, knowledge about the 
two single-subunit OST essentiality in bloodstream form parasites was gathered 
(Izquierdo et al., 2009a). Both proteins were found to be non-essential in vitro when 
knocked down individually, however, simultaneous knockdown caused a cessation in 
cell growth and proved that protein N-glycosylation is essential in T.brucei. 
Interestingly, individual knockdown of either TbSTT3A or TbSTT3B was found to 
abolish the ability of the parasite to infect mice, highlighting that both TbSTT3A and 
TbSTT3B glycosylation mechanisms are independently essential in vivo(Izquierdo et 
al., 2009a). 
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Figure 1.10.Schematic view of lipid-linked oligosaccharide and sequon specificity in 
T. brucei.Man5GlcNAc2 is recognised and co-translationally transferred to selected 
sequons surrounded by acidic amino acids (highlighted in red in nascent protein)by 
TbSTT3A. Man9GlcNAc2 is recognised and post-translationally transferred to any 
remaining, sterically accessible sequons (independent of surrounding pH) by 
TbSTT3B. TbSTT3A transfer is dependent on the LLO not having a C-branch, 
whereas TbSTT3B require the C-branch for efficient LLO transfer (Izquierdo et al., 
2009a, 2012).  
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1.5 Aim of the thesis 
 
The project wasdivided in three component parts: 
1. Generation of TbSTT3A gene replacement mutants and analysis of their 
biochemical and biological phenotype. 
2. TbOST localisation studies and search for novel TbSTT3A binding partners. 
3. Testing the sequon specificity of TbSTT3A and TbSTT3B in vivo. 
 
1. The aim of this project is to investigate the essentiality and function of TbSTT3A and 
the families of N-glycans they are ultimately responsible for in mature T. brucei 
glycoproteins. To address these goals, gene replacement experiments in order to 
generate null and/or conditional null mutants of TbSTT3A, will be performed. 
2. For the localisation and putative TbOST subunits studies, endogenous TbSTT3A will 
be in situ tagged. This tag enables both immunolocalisation and immunoprecipitation 
experiments which will help elucidate where in the cell TbSTT3A is localised and if it 
has any binding partners. 
3. Using a glycosylation reporter protein, N-linked sequon specificity of TbSTT3A and 
TbSTT3B will be investigated in order to investigate the role of flanking residues 
involvement in N-glycosylation. 
 
Figure 1.10.(continued)The biantennary Man5GlcNAc2 is the only route to 
paucimannose and complex oligosaccharides, while the triantennary Man9GlcNAc2 
can only be processed to oligomannose glycans because of the lack of a Golgi α-
mannosidase II gene (Manthri et al., 2008). 
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2 – Materials and Methods 
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2.1 Materials 
 
All reagents, enzymes and chemicals used in this study were of the highest grade and 
purity available from commercial companies.   
 
2.2 Parasite culture 
 
2.2.1 T. bruceicell lines and media 
 
Strain 427 of T. brucei bloodstream form cells were grown in HMI-9t medium 
supplemented with glutamax at 37°C with 5% CO2. HMI-9t is similar to the HMI-9 
medium previously described earlier (Hirumi and Hirumi, 1989), but thioglycerol has 
replaced β-mercaptoethanol. Parasites were grown in tissue culture flasks with filter lids 
to a maximum density of 5x10
6
 cells/ml. The cell line which was used in the 
experiments was the single marker (sm) cell line, which expresses a tetracycline 
repressor protein (TetR) and a T7 polymerase (Wirtz et al., 1999) under neomycin 
(G418) selection. Table 2.1 gives the antibiotic concentration used to maintain 
selection. 
 
Table 2.1. Antibiotics used in T. brucei cell culture and genetic manipulation 
Antibiotic Resistance gene Concentration µg/ml 
Neomycin (G418) Neomycin phosphotransferase 2.5 
Hygromycin Hygromycin phosphotransferase 4 
Phleomycin Phleomycin resistance protein 0.1 
Puromycin Puromycin acetyltransferase 2.5 
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Blasticiden Blasticidin deaminase 2.5 
Tetracycline  0.5 
2.2.2 General T. brucei cell culture protocols 
 
2.2.2.1 Cell density 
Cells were counted with the CASY® Cell Counter + Analyser system, which measures 
the cell density in the culture. Alternatively, cells were counted in a haemocytometer, 
diluted 1:10 in 1x trypanosome dilution buffer (TDB)(Table 2.2). 
 
Table 2.2. 5x Trypanosome Dilution Buffer (TDB) 
Chemical substances Concentration (M) 
KCl 0.025 
NaCl 0.4 
MgSO4●H2O 0.005 
Na2HPO4 0.1 
NaH2PO4●H2O 0.01 
Glucose 0.1 
 
2.2.2.2 Generation of stabilates 
Cells were grown to mid log phase (1-3x106 cells/ml), centrifuged (800 g, 10 min, 4°C 
on 4K15 Sigma centrifuge) and resuspended in half of the starting volume HMI-9t 
medium, containing 10% glycerol and no antibiotics. Aliquots of 0.5 ml were frozen in 
2 ml Cryovials (Nalgene). 
 
2.2.2.3 T. brucei crude cell lysate 
Cells were grown to mid log phase density and 3x107 cells were harvested by 10 min 
centrifugation (4K15 Sigma Centrifuge) at 4°C. Cells were washed twice in TDB buffer 
at 4°C. After the last wash, cells were transferred to a 1.5 ml tube and pelleted for 30s at 
11000 g (Centrifuge 5417R, Eppendorf). The cells were then resuspended in 1xTDB 
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buffer and lysed by addition of an equal volume of 2% SDS sample buffer 
(Invitrogen).The cell lysate was heated to 95°C for 10 min before loading on a gradient 
SDS-PAGE gel (Invitrogen). 
 
2.2.2.4 T. brucei bloodstream form electroporation 
Cells were grown to mid log phase density (1-3x106 cells/ml),centrifuged (800 g, 10 
min, 20°C) and resuspended in Amaxa® Human T-Cell Nucleofector solution 
containing supplement (Lonza) so that the final concentration was 1x108 cells/ml. 100 
µl was transferred to cuvettes (Amaxa certified, included in the Nucleofector kit) 
containing 1 µg of plasmid DNA each.One cuvette contained no DNA and was used as 
a negative control. The cells were electroporated using an Amaxa Nucleofector® II, 
program X-001 (Burkard et al., 2007). Subsequent to electroporation, the cells from 
each cuvette were transferred in a flask with 50 ml of HMI-9t containing all necessary 
antibiotics except the selection antibiotic for the electroporated construct. The cells were 
left to recover for 6-8 h at 37°C before the selection antibiotic was added. When the 
control cells, electroporated without any DNA construct and hence no antibiotic 
resistance gene, were dead, resistant clones were established in culture, stabilated and 
their genotype analysed by Southern blot. 
 
2.3 General molecular biology 
 
2.3.1 Primers 
 
Primers were designed to contain ~20 bp of complementary sequence, preferably with a 
guanine (G) or cytosine (C) at their 3’ end and an approximate melting temperature 
(Tm) of 68°C. The melting temperaturewas calculated by the following formula: Tm= 
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(G+C)x 4°C + (A+T)x 2°C.Only the nucleotides in the complementary sequence of the 
primer were considered in the calculations. All primers were synthesized by the 
Oligonucleotide Synthesis Service, University of Dundee. Primers used are listed in 
table 2.3. 
 
Table 2.3. List of primers 
 
Function Primers Sequence 
Knock out 5’ UTR Fw ATAAGTATGCGGCCGCAAATGTCCATCGACTCTCATTCC 
Knock out 5’ UTR Rev GTTTAAACTTACGGACCGTCAAGCTTTAAGCAGAAAGAAAC
GCCCAAAG 
Knock out 3’ UTR Fw GACGGTCCGTAAGTTTAAACGGATCCGTCGAAAACCTGTATT
TTCAGAGC 
Knock out 3’ UTR Rev ATAAGTAAGCGGCCGCCTATTCCTTTGCCCTCGGACG 
   
Ectopic copy STT3A Fw ATAAGTATAAGCTTATGACGAAAGGTGGGAAAGTAGC 
Ectopic copy STT3A Rev ATAAGTAAGGATCCTAGCGAAGCGGTTCCATTACGAA 
   
In situ tagging STT3A 4YH 
5’ Fw 
AGTATAAAGGTACCGTTACCCTCTTTGGGGGTGCG 
In situ tagging STT3A 4YH 
5’ Rev 
TTACTTATGGGCCCTTCGTAATGGAACCGCTTCGCT 
In situ tagging STT3A 4YH 
3’ Fw 
ATAATGAAGCGGCCGCTGACCACATCGTTTCAATCGCC 
 
In situ tagging STT3A 4YH 
3’ Rev 
TTACTTATCCACCGCCGTGGGCGACGAACGTAGTGGATGAC 
In situ tagging STT3A 4H 
5’ Fw 
ATAAGTATCTCGAGCAAGTTTGCTTGCCCCGTTCG 
In situ tagging STT3A 4H ATAAGTAACTCGAGCTCGCTCTGAAAATACAGGTTTTCGACT
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5’ Rev TCGTAATG 
GAACCGCTTCGCT 
In situ tagging STT3A 4H 
3’ Fw 
ATAAGTATGGATCCCCACATCGTTTCAATCGCCGC 
In situ tagging STT3A 4H 
3’ Rev 
ATAAGTAAGGATCCACTCACAATCGTGCTTACAGCC 
   
Southern blot 
probe 
STT3A 
probe Fw 
CCCTCTTTGGGGGTGCGGTG 
 
Southern blot 
probe 
STT3A 
probe Rev 
ATTGGGTAGATCAGTCACGGCA 
 
Southern blot 
probe 
STT3A/B/C 
probe Fw 
TTGGCCGACCGGTGGGCAC 
Southern blot 
probe 
STT3A/B/C 
probe Rev 
GCGTCCACTCCACTGGCGGT 
   
PCR knock 
out control 
Upstream 5’ 
UTR Fw 
GCAGAAGCGACAACTAGACCTC 
PCR knock 
out control 
3xHA rev CTATGCGTAATCGGGCACATCGT 
PCR knock 
out control 
BSD Rev TTGTAGCCGTTGCTCTTTCAATG 
   
BipN reporter 
protein 
BipN Fw ATAAGTATAAGCTTATGTCGAGGATGTGGC 
BipN reporter 
protein 
BipN Rev ATAAGTAAAATTAATTCCTAGGCCCGCCAACCTCGCTTTCAC 
 
   
Glycosequon 
assay 
STT3B 1 Fw CTAGGGCGGCGGCGGATTTCAATAGGCGGAATCGCTCGGAT
GCTTACTATAGAC 
Glycosequon STT3B 1 AATTGTCTATAGTAAGCATCCGAGCGATTCCGCCTATTGAAA
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assay Rev TCCGCCGCCGCC 
Glycosequon 
assay 
STT3A/B 1 
Fw 
CTAGGGCGGCGGCGTATTTGTGGCTAAGAAACTCGACACCG
GAAGATGCCAGGC 
Glycosequon 
assay 
STT3A/B 1 
Rev 
AATTGCCTGGCATCTTCCGGTGTCGAGTTTCTTAGCCACAAA
TACGCCGCCGCC 
Glycosequon 
assay 
STT3A/B 2 
Fw 
CTAGGGCGGCGGCGATTACAGGGATCGGTAACAGGACGACC
CTGGCGGACGGTC 
Glycosequon 
assay 
STT3A/B 2 
Rev 
AATTGACCGTCCGCCAGGGTCGTCCTGTTACCGATCCCTGTA
ATCGCCGCCGCC 
Glycosequon 
assay 
STT3A/B 3 
Fw 
CTAGGGCGGCGGCGATATATAAGGTGATGAATGTTTCGGAG
GAATCGAAAGCAC 
Glycosequon 
assay 
STT3A/B 3 
Rev 
AATTGTGCTTTCGATTCCTCCGAAACATTCATCACCTTATATA
TCGCCGCCGCC 
Glycosequon 
assay 
Transferrin 1 
Fw 
CTAGGGCGGCGGCGGAAAGAAATGCACTGAACGCTACTGCT
GCGAATAAAGTGC 
Glycosequon 
assay 
Transferrin 1 
Rev 
AATTGCACTTTATTCGCAGCAGTAGCGTTCAGTGCATTTCTTT
CCGCCGCCGCC 
Glycosequon 
assay 
Transferrin 2 
Fw 
CTAGGGCGGCGGCGCTTGAAGAGATGAGAAACGCCTCAGCG
CTCGCAGCCGCGGCGC 
Glycosequon 
assay 
Transferrin 2 
Rev 
AATTGCGCCGCGGCTGCGAGCGCTGAGGCGTTTCTCATCTCT
TCAAGCGCCGCCGCC 
Glycosequon 
assay 
Transferrin 3 
Fw 
CTAGGGCGGCGGCGACGATACTTAAGTCGAATTATACTGCA
GAACCGGTGAGGC 
Glycosequon 
assay 
Transferrin 3 
Rev 
AATTGCCTCACCGGTTCTGCAGTATAATTCGACTTAAGTATC
GTCGCCGCCGCC 
Glycosequon 
assay 
Transferrin 4 
Fw 
CTAGGGCGGCGGCGGAACGAAACGCTCTGAACGCTACCGCC
GCTAATAAAGTAC 
Glycosequon 
assay 
Transferrin 4 
Rev 
AATTGTACTTTATTAGCGGCGGTAGCGTTCAGAGCGTTTCGT
TCCGCCGCCGCC 
Glycosequon 
assay 
Transferrin 5 
Fw 
CTAGGGCGGCGGCGTCTCCCACCAGGCACAACCTAACCTGG
GGAGGTGGTGTTC 
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Glycosequon 
assay 
Transferrin 5 
Rev 
AATTGAACACCACCTCCCCAGGTTAGGTTGTGCCTGGTGGGA
GACGCCGCCGCC 
Glycosequon 
assay 
Transferrin 6 
Fw 
CTAGGGCGGCGGCGTTTGGGTCATATCAGAACGGTTCAATGT
ATGTAGAGGGCC 
Glycosequon 
assay 
Transferrin 6 
Rev 
AATTGGCCCTCTACATACATTGAACCGTTCTGATATGACCCA
AACGCCGCCGCC 
Glycosequon 
assay 
Transferrin 7 
Fw 
CTAGGGCGGCGGCGGTGTGCCTCAATCGCAACTTCACTTGGG
GCGGGGGTGTCC 
Glycosequon 
assay 
Transferrin 7 
Rev 
AATTGGACACCCCCGCCCCAAGTGAAGTTGCGATTGAGGCA
CACCGCCGCCGCC 
Glycosequon 
assay 
Alanine 
control Fw 
CTAGGGCGGCGGCGGCGGCGGCGGCGGCGAACGCGACGGC
GGCGGCGGCGGCGC 
Glycosequon 
assay 
Alanine 
control Rev 
AATTGCGCCGCCGCCGCCGCCGTCGCGTTCGCCGCCGCCGCC
GCCGCCGCCGCC 
Glycosequon 
assay 
D1 Fw CTAGGGCGGCGGCGGATGCTGCGGCCGCAAATGCAACAGCC
GCAGCAGCAGCGC 
Glycosequon 
assay 
D1 Rev AATTGCGCTGCTGCTGCGGCTGTTGCATTTGCGGCCGCAGCA
TCCGCCGCCGCC 
Glycosequon 
assay 
D2 Fw CTAGGGCGGCGGCGGCCGATGCAGCCGCGAATGCGACGGCC
GCCGCTGCAGCCC 
Glycosequon 
assay 
D2 Rev AATTGGGCTGCAGCGGCGGCCGTCGCATTCGCGGCTGCATC
GGCCGCCGCCGCC 
Glycosequon 
assay 
D3 Fw CTAGGGCGGCGGCGGCAGCCGATGCGGCCAATGCTACGGCC
GCTGCAGCCGCAC 
Glycosequon 
assay 
D3 Rev AATTGTGCGGCTGCAGCGGCCGTAGCATTGGCCGCATCGGCT
GCCGCCGCCGCC 
Glycosequon 
assay 
D4 Fw CTAGGGCGGCGGCGGCAGCTGCAGATGCGAACGCCACGGCC
GCGGCTGCTGCCC 
Glycosequon 
assay 
D4 Rev AATTGGGCAGCAGCCGCGGCCGTGGCGTTCGCATCTGCAGC
TGCCGCCGCCGCC 
Glycosequon D5 Fw CTAGGGCGGCGGCGGCTGCCGCCGCTGACAATGCAACAGCC
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assay GCGGCCGCGGCAC 
Glycosequon 
assay 
D5 Rev AATTGTGCCGCGGCCGCGGCTGTTGCATTGTCAGCGGCGGCA
GCCGCCGCCGCC 
Glycosequon 
assay 
D6 Fw CTAGGGCGGCGGCGGCTGCAGCTGCTGCGAATGACACCGCA
GCTGCGGCAGCCC 
Glycosequon 
assay 
D6 Rev AATTGGGCTGCCGCAGCTGCGGTGTCATTCGCAGCAGCTGCA
GCCGCCGCCGCC 
Glycosequon 
assay 
D7 Fw CTAGGGCGGCGGCGGCGGCCGCGGCCGCAAATGCTACAGAT
GCAGCGGCCGCAC 
Glycosequon 
assay 
D7 Rev AATTGTGCGGCCGCTGCATCTGTAGCATTTGCGGCCGCGGCC
GCCGCCGCCGCC 
Glycosequon 
assay 
D8 Fw CTAGGGCGGCGGCGGCGGCCGCCGCAGCAAACGCGACCGCG
GATGCCGCCGCAC 
Glycosequon 
assay 
D8 Rev AATTGTGCGGCGGCATCCGCGGTCGCGTTTGCTGCGGCGGCC
GCCGCCGCCGCC 
Glycosequon 
assay 
D9 Fw CTAGGGCGGCGGCGGCTGCGGCAGCAGCGAACGCGACAGCG
GCAGATGCAGCGC 
Glycosequon 
assay 
D9 Rev AATTGCGCTGCATCTGCCGCTGTCGCGTTCGCTGCTGCCGCA
GCCGCCGCCGCC 
Glycosequon 
assay 
D10 Fw CTAGGGCGGCGGCGGCAGCGGCAGCGGCGAACGCGACGGCT
GCTGCCGATGCAC 
Glycosequon 
assay 
D10 Rev AATTGTGCATCGGCAGCAGCCGTCGCGTTCGCCGCTGCCGCT
GCCGCCGCCGCC 
Glycosequon 
assay 
D11 Fw CTAGGGCGGCGGCGGCCGCCGCGGCTGCTAACGCGACCGCG
GCGGCGGCAGACC 
Glycosequon 
assay 
D11 Rev AATTGGTCTGCCGCCGCCGCGGTCGCGTTAGCAGCCGCGGC
GGCCGCCGCCGCC 
   
Point 
mutation 
STT3B 
H397R Fw 
GTGGATTCTGTGGCTGAGCACCGTCCGGCGTCGAATGATGAT
TTC 
Point STT3B GAAATCATCATTCGACGCCGGACGGTGCTCAGCCACAGAAT
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mutation H397R Rev CCAC 
Point 
mutation 
STT3C 
R397H Fw 
GTGGATTCTGTGGCTGAGCATCACCCGACGACTGCCGGGGC
CTTC 
Point 
mutation 
STT3C 
R397H Rev 
GAAGGCCCCGGCAGTCGTCGGGTGATGCTCAGCCACAGAAT
CCAC 
Point 
mutation 
STT3C 
R397D Fw 
GTGGATTCTGTGGCTGAGCATGACCCGACGACTGCCGGGGC
CTTC 
Point 
mutation 
STT3C 
R397D Rev 
GAAGGCCCCGGCAGTCGTCGGGTCATGCTCAGCCACAGAAT
CCAC 
Point 
mutation 
STT3C 
R397Q Fw 
GTGGATTCTGTGGCTGAGCATCAGCCGACGACTGCCGGGGC
CTTC 
Point 
mutation 
STT3C 
R397Q Rev 
GAAGGCCCCGGCAGTCGTCGGCTGATGCTCAGCCACAGAAT
CCAC 
 
 
2.3.2 List of plasmid vectors 
 
Table 2.4. List of plasmids 
Plasmid Use Source 
pGEM5Zf Gene replacement constructs Promega 
pLEW100 Protein expression under tetracycline-inducible control Wirtz et al 
pLEW82 Protein expression under tetracycline-induciblecontrol Wirtz et al 
pMOTag4YH In situ tagging Oberholzer et al 
pMOTag4H In situ tagging Oberholzer et al 
pSC-A-amp/kan General cloning StrataClone 
pXS5 BipN generation Jay Bangs 
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2.3.3 PCR 
 
All polymerase chain reactions (PCRs) for amplification of UTRs, ORFs, and Southern 
probe were performed using a PTC-225 Peltier Thermal Cycler (MJ Research). 
Reactions were run with the Kod Hot Start Polymerase in a 50 µl volume as per the 
manufacturer’s standard protocol using the appropriate primers (Table 2.1). The 
template concentrations used ranged from 1-10 ng for gDNA and 10-100 pg for purified 
plasmid DNA and optimised for each target of interest. 
When joining the UTRs in the gene replacement construct, the two UTRs were first 
annealed via the previously introduced complementary sequence (in the absence of 
primers) followed by amplification of the combined UTR fragment by the addition of 
the 5’ UTR Fw and 3’ UTR Rev primers (Table 2.5). 
 
Table 2.5. Annealing PCR reaction for joining UTRs 
 
 
 
 1   95               30 sec
 1   95               30 sec 
 1   50                       45 sec 
 1   68               1 min  
  
1   95               30 sec
 1   95               30 sec 
 1   60                       45 sec 
 1   68               1 min 
               1              68                      10 min  
x25 
   Reaction Mix (per 50 µl) 
   5 µl of 10x KOD Hot PCR Buffer 
   5 µl dNTPs (0.2mM each) 
   2 µl MgSO4(1mM) 
   50 ng each UTR fragment  
   1 µl KOD Hot Start DNA polymerase (1U)    
   up to 50 µl with nuclease-free H2O 
 
    after linking PCR add: 
   1.5 µl 5’ UTR – F primer (15 pmol) 
   1.5µl 3’ UTR – R primer (15 pmol) 
                  Amplification Program 
    #of Cycles      T (ºC)                    Time 
x5 
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2.3.4 Agarose gel electrophoresis 
 
Agarose gel eletrophoresis was used for separation of DNA. Gels for general DNA 
analysis were made with 1 % w/v agarose (Electran agarose, VWR) in 1x TAE (40 mM 
Trisacetate, 1 mM EDTA) buffer containing 0.4 µg/ml ethidium bromide, while 0.8% 
gels were used for Southern blotting. The gels were run at 80 V in 1x TAE, with the 
exception of agarose gels for Southern blotting that were run at 40 V,until the desired 
separation was achieved. The separation of a DNA marker (1 kbp DNA ladder, 
Promega) allowed the size of the samples to be estimated by comparing the relative 
migrations through the gel.  Gels were imaged by UV transillumination.  
 
2.3.5 Gel extraction of DNA fragments and plasmid DNA 
 
To purify DNA fragments and plasmid vectors obtained from PCR or endonuclease 
digestions following separation on agarose gel, QIAquick® Gel Extraction Kit (Qiagen) 
was used following kit intructions. DNA concentration was estimated by A260 at the 
spectrophotometer (Nanovue). 
 
2.3.6 Transformation 
 
Transformation of plasmids was achieved by heat shock of competent cells. Typically, 
10 ng of purified plasmid DNA was mixed with 50 ul chemically competent cells 
(Bioline α-select silver, Agilent technologies XL10 gold, StrataClone Solopack) and 
incubated on ice for 30 minutes before being subjected to heat chock at 42°C for 30 
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seconds followed by cooling the cells on ice for 2 minutes. Subsequently, SOC medium 
was added to the cells which were then grown 1 h at 37 °C, 200 rpm before being plated 
on LB agar plates containing ampicillin. Colonies were selected after overnight growth 
at 37 °C. 
 
2.3.7 E. coli strains and cultures 
 
E. coli cells (DHα5, Top10 one shot, Silverselect – Invitrogen and Novagen clonable 
cells) were grown in LB medium containing 50 µg/ml ampicillin at 37°C, 200 rpm. 
After transformation, colonies were selected on LB agar plates grown at 37°C for 16 h. 
For bacterial stabilates, cells were mixed 1:1 with 80% glycerol (AnalaR, VWR) and 
freezed on dry-ice before storage at -80°C. All media were obtained from the Media 
Kitchen service in theCollege of Life Sciences, University of Dundee. 
 
2.3.8 Dephosphorylation 
 
Following endonuclease digestion, plasmids were dephosphorylated to reduce the re-
ligation. The plasmids were incubated at 37°C for 30 min with Antartic phophatase 
(New England Biolab) following by inhibitionof the reaction by heating at 65°C for 20 
min. 
 
2.3.9 Ligation 
 
Ligations were made by using the Rapid DNA Ligation kit (Roche) or the Clonables 
kit(Merck Millipore). Typically, the concentrations of digested vector and inserts were 
estimated at the spectrophotometer (A260) and by running an analytical agarose gel 
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where the DNA bands could be compared. Vector and inserts were mixed accordingly 
to the manufacture’s protocols and an additional reaction without insert was run as a 
control for the vector re-ligation background. 
2.3.10 DNA sequencing 
 
DNA sequencing was performed by the Sequencing Service, University of Dundee. The 
consensus sequence was built using or CLC Main Workbench 6.9.1. 
 
2.3.11 Site-Directed Mutagenesis 
 
Site directed mutagenesis was used to introduce a TEV site into the pMOTag4YH and 
pMOTag4H plasmids in addition to generate point mutations at position 397 in 
TbSTT3B and TbSTT3C. The QuickChange® Site-Directed Mutagenesis Kit 
(Stratagene) was used according to manufacturer’s instructions. The primers used are 
listed in Table 2.1. 
 
2.3.12 Ethanol precipitation of DNA 
 
Ethanol precipitation of genomic DNA was done using 3 M sodium acetate pH 5 (1/10 
of DNA solution volume) which was supplemented by absolute ethanol (3 times the 
total volume of DNA plus sodium acetate). The mix was incubated at -20°C for at least 
16 h or alternatively 30 min on dry ice. To resuspend the precipitated DNA, the mix 
was centrifuged at 4 °C for 10 min at 16000 g and the supernatant was decanted 
followed by the pellet being washed with ice cold 70% ethanol. After decanting the 
wash, the ethanol was left to air-dry and then the pellet was resuspended in buffer or 
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sterile water. Finally, purified samples were confirmed to be pure by spectrophotometry 
(260:280 ratio >1.8). 
 
2.3.13 Genomic DNA isolation 
 
Bloodstream form T. brucei were grown to log phase density and ~1x108 cells were 
harvested by centrifugation for 10 min at 4 °C, 800 g. Cells were then lysed in 1 ml 
DNAzol™ and incubated at least 30 min at room temperature. Subsequently, 0.5 ml of 
absolute ethanol was added and the cell lysate was centrifuged for 10 minutes at 16000 
g. The supernatant was decanted and the remaining pellet washed twice with 70% ice 
cold ethanol (10 min, 16000 g). Subsequent to decanting the wash, the pelleted genomic 
DNA was left to air-dry (~10 min) before being dissolved in 50 µl of H2O and heated to 
50 °C for about 4 h.  
 
2.3.14 Southern blotting 
 
Genomic DNA (~ 5 ug) was digested for 16 h with specific restriction endonucleases 
and run (40 V) on a 0.8 % agarose gel containing ethidium bromide. Afterwards, the gel 
was washed 5 minutes in 1x TAE before continuing washing it 10 minutes in 0.2 M 
HCl, 15 min in 0.5 M NaOH, 1.5 M NaCl and twice for 20 min in 1 M TrisHCl, 1.5 M 
NaCl pH 7.5 to prepare for transfer. The DNA was transferred to a positively charged 
nylon membrane (Roche) by capillary mechanism as described in Figure 2.1. The 
transfer was performed overnight in 10x sodium chloride, sodium citrate buffer (SSC). 
Subsequently, the DNA was crosslinked to the membrane using 1200 UV counts on a 
CL-1000 (UVP) UV crosslinker. 
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2.3.15 DIG-labelled probe detection 
 
The DNA probes used were generated using the PCR DIG Probe Synthesis Kit (Roche). 
A 5 ul aliquot was analyzed by agarose gel electrophoresis to control that a single band 
was produced and that there was a size increase in the labelled probe compared to 
unlabelled negative control. When a bright single band was observed, 45 µl of probe /45 
ml of hybridization buffer were used. The membrane was placed in a roller bottle 
(Techne) and pre-hybridized in EasyHyb solution (Roche) at 42°C for 30 min in a 
Hybridized HB-1D oven (Techne). Before use, the probe was denatured by heating for 
100°C for 5 min and quickly cooled on ice, and subsequently added to a fresh aliquot of 
EasyHyb solution. The membrane was then hybridized overnight at 42°C. Following 
hybridization, the membrane was washed twice for 5 min in 1x SSC, 0.1% SDS at 42°C 
and twice for 15 min in pre-warmed 0.5x SSC, 0.1% SDS at 65°C. The membrane was 
then equilibrated for 5 min at room temperature in 1x wash buffer before being blocked 
for 30 min in blocking solution (DIG wash and block buffer set, Roche). After blocking, 
the membrane was incubated for 30 min with Anti-DIG AP-conjugate antibody 
Figure 2.1. Southern blot transfer set up of fragmented gDNA from the agarose gel 
to the nylon membrane. 
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(Roche)at a 1:10000 dilution in blocking buffer of, followed by two 15 min washing 
steps in 1x wash buffer and a 5 min equilibration step in 1x detection buffer. The 
membrane was placed in a plastic folder and CSPD detection reagent (Roche) was 
applied in a drop wise manner. The membrane was incubated 5 min at room 
temperature in the dark and 10 min at 37°C. Films (Hyperfilm™ ECL, Amersham) were 
exposed from 30 sec to 5 min and developed with a Compact X4 developer. 
 
2.4 Protein biochemistry 
 
2.4.1 SDS-PAGE 
 
All SDS-PAGE were run using pre-cast Novex Bis-Tris gels (4-12%, 10% or 12%) with 
MOPS running buffer (50 mM MOPS, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 
7.7 - Invitrogen) in n XCELL-II mini tank (Novex) at 200 V using a BioRad Power Pac 
Junior. Samples were prepared using 4x SDS Sample buffer (200mM Tris-HCl pH 6.8, 
400 mM DTT, 8 % SDS, 0.4 % bromophenol blue and 40 % glycerol – Invitrogen) and 
a final concentration of 0.1 M DTT as reducing agent. Before loading, samples were 
heated at 100°C for 10 min. 
 
2.4.2 Coomassie staining 
 
After desired separation was achieved, proteins were stained by incubating for 1 h with 
0.1% Coomassie brilliant blue stain in 40% methanol, 10% acetic acid. The excess stain 
was removed by washing the gel in destain solution (40% methanol, 10% acetic acid) or 
in H2O. For peptide mass fingerprinting, the gel was stained for 1 h min with 
SimplyBlue™ Safe Stain (Invitrogen) and destained in water.  
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2.4.3 Western blotting 
 
After separation by SDS-PAGE, proteins were transferred on a nitrocellulose membrane 
(iBlot gel transfer stack) using a iBlot system (Invitrogen) according to manufacturer’s 
instructions. The membrane was incubated for 5 min in Ponceau S (Sigma) before being 
blocked in 50 mM TrisHCl, 0.15 M NaCl, 0.05 % Tween 20, 0.25 % BSA,0.05 % Na 
and 2 % FSG pH 7.4 (Blocking buffer) for 20 min. The membrane was then incubated 
for 30 min with primary antibody in a 50 ml Falcon tube followed by washing using the 
SnapID system. Subsequently, the secondary antibody was incubated for 30 min and 
again followed by a washing step. Both these steps were carried out using the SnapID. 
 
2.4.4 Western blot development 
 
Proteins separated on SDS-PAGE gels were imaged using an ODYSSEY® SA near 
infrared imager (LI-COR Biosciences).Secondary LI-COR antibodies (IRDye-800CW 
goat anti-mouse 1:15000 or IRDye-680RD donkey anti mouse 1:20000) were used to 
bind the primary antibodies that had bound to the specific tags. Gels were scanned with 
a resolution of 50 µm using the appropriate sensitivity settings for each channel and a 
focal path length of 3.5 mm.  Coloured images were sometimes converted to grayscale 
and, when needed, proteins were quantified in Image Studio Lite version 3.1 (LI-COR 
Biosciences).  
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2.4.5 Immunoprecipitaion 
 
100 ml of cells culture were grown to log phase (approximately 2.5x106 cells/ml) and 
lysed in lysate buffer (see table 2.7) for 30 min on ice (Lysis buffer 2 and 3) or by 
boiling for 10 min (lysis buffer 1). Subsequently, the lysate was centrifuged (4°C, 
11000g, 15 min) and the supernatant was moved to a new tube. When using lysis buffer 
1, the lysate was diluted 1:30 in 50 mM Tris HCl pH 6.8, 20 mM EDTA and the 
protease inhibitors mentioned earlier. Pre-washed protein G magnetic beads were added 
to the lysate in order to absorb a majority of the nonspecific binding to the beads. After 
30 min incubation (4°C with slow spin) the magnetic beads were captured and the lysate 
moved to a new tube followed by an hour incubation with antibody (4°C, slow spin). 
The different antibodies used are listed in table 2.6. Next, the magnetic beads were 
again captured with a magnet and the flow through removed before washing twice with 
1 ml lysis/IP buffer. The final wash was done in wash buffer 2 (10 mM Tris-HCL, 4 
mM EDTA, 0.1 % digitonin) containing the same protease inhibitors as mentioned 
earlier.  To elute, 15 ul 1xPBS buffer, 4x sample load and 1 ul 1 M DTT was added to 
the beads, followed by boiling at 100°C for 10 min. The eluted proteins where 
subsequently separated on a SDS-PAGE gel. 
 
Table 2.6. List of antibodies used for immunoprecipitation. 
Antibody Concentration Supplier 
αHA 1µg/ml In house 
αHA precoupled 1µg/ml Pierce 
αMYC precoupled 1µg/ml Pierce 
αGFP 1µg/ml Roche 
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Table 2.7.List of lysis buffers. 
Lysis buffer 1 1 % SDS, 0.1 M DTT, PMSF, TLCK, Mini EDTA free protease inhibitor 
tablet 
Lysis buffer 2 1 % TritonX, 50 mM Tris HCl pH 6.8, 20 mM EDTA, PMSF, TLCK, Mini 
EDTA free protease inhibitor tablet 
Lysis buffer 3 0.5 % digitonin, 50 mM Tris HCl pH 6.8, 20 mM EDTA, PMSF, TLCK, 
Mini EDTA free protease inhibitor tablet 
 
2.4.6 Blue native gel and Western blotting 
 
Blue Native gel electrophoresis was run using components from the Native Page kit 
(Invitrogen). The protocol was followed to the manufacture’s instructions with a few 
exceptions. No G-250 sample additive was added to the protein samples. The 1x 
NativePage Light Cathode buffer was diluted 1:4 in 1x running buffer to reduce 
coomassie interference for the following Western blot and image development.  
 
2.5 SILAC 
 
2.5.1 SILAC labelling 
 
SILAC IMDM media (Thermo Scientific) was supplemented with the ingredients listed 
in table 2.8. After adjusting the pH to 7.4, either normal L-arginine and L-lysine 
(HMI11-SILAC + R0K0) or L-arginine U-
13C6 and L-lysine 4,4,5,5-
2H4 (HMI11-SILAC 
+ R6K4) was added to the media (120 and 240 uM respectively) which was then sterile 
filtered (TPP vakuumfiltration 500). Cells were split into either heavy or light labelled 
SILAC media with a dilution factor of 1:1000 and cells were subsequently grown to log 
phase before starting the IP experiment. 
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2.5.2 SILAC IP 
 
Heavy and light label cells were spun down individually (15 min, 800 g, 4 °C), washed 
in TDB before being resuspended in 1 ml 1xTDB for accurate cell counting. The cells 
were then mixed 1:1 before treated as described in the IP protocol, using lysing buffer 1. 
When to elute, 12 µl wash buffer 2 (10 mM Tris-HCL, 4 mM EDTA, 0.1 % digitonin), 
10 µl 4x loading buffer and 5 µl 50 mM DTT (Clealand reagent) was added to the 
captured beads and the mixture was boiled at 100°C. 2 µl of the sample was analysed by 
Western blotting to verify that the tagged protein had been immunoprecipitated and, if 
so, the remaining 25 µl was handed to the proteomics facilities for further preparations. 
 
2.6 Mass spectrometry and data processing 
 
2.6.1 Mass spectrometry 
 
All trypsin digestion and mass spectrometry was carried by the FingerPrints proteomic 
service at the University of Dundee (http://proteomics.lifesci.dundee.ac.uk)  
SILAC protein samples were alkylated by adding 5 µl of 300 mM iodoacetamide and 
incubation at room temperature for 30min in the dark. Samples were loaded on novex 
NUPAGE 4-12% Bis Tris gel and run at 200 V using MOPS buffer until the protein 
have migrated 2 cm into the gel. Proteins were stained with simply blue safe stain for 
1hr and then destained by gentle shaking in MilliQ water followed by in gel digestion. 
Protein bands were cut with a clean scalpel blade, transferred to a micro-centrifuge tube 
and cut into small pieces. Gel pieces were washed with Milli-Q water (200 µl), 200 µl 
of acetonitrile, 200 µl of 100 mM ammonium bicarbonate, 200 µl 100 mM ammonium 
bicarbonate and 50% acetonitrile and finally 100 µl acetonitrile for 15 min each step. 
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Gel pieces were then air dried in a laminar flow cabinet. In-gel digestion is carried out 
by 1µg (1µl) of trypsin, incubated overnight at 30oC. An equal volume of acetonitrile 
(i.e. 100 µl) was added and the peptide mixtures were extracted by vigorous shaking 
(1,000 rpm) at room temperature for 10 min. The resulting supernatant was then 
transferred to a fresh microcentrifuge tube. Peptides in the gel pieces were further 
extracted twice with 5% formic acid (100 µl) and 100% acetonitrile (100 µl) with 20 
min incubation each on the shaker. The supernatant was then collected and transferred 
to the first fraction. The gel pieces were washed for a third time with acetonitrile (100 
µl) and incubated for a further 10 min. The pooled three fractions were dried in 
SpeedVac and stored at -20oC until further processing. 
Following digestion, peptides from various samples were reconstituted in 50 µl 1% 
formic acid and 10 µl were analysed on a Velos pro-orbitrap (Thermo Scientific) mass 
spectrometer coupled with a Dionex Ultimate 3000 RS (Thermo Scientific). LC buffers 
were the following: buffer A (2% acetonitrile and 0.1% formic acid in Milli-Q water 
(v/v)) and buffer B (80% acetonitrile and 0.08% formic acid in Milli-Q water (v/v). 
Aliquots of 2 µL of each sample were loaded at 5 µL/min onto a trap column (100 µm × 
2 cm, PepMap nanoViper C18 column, 5 µm, 100 Å, Thermo Scientific) equilibrated in 
98% buffer A. The trap column was washed for 3 min at the same flow rate and then the 
trap column was switched in-line with a Thermo Scientific, resolving C18 column (75 
µm × 50 cm, PepMap RSLC C18 column, 2 µm, 100 Å). The peptides were eluted from 
the column at a constant flow rate of 300 nl/min with a linear gradient from 98% buffer 
A to 40% buffer B in 128 min, and then to 98% buffer B by 130 min. The column was 
then washed with 98% buffer B for 20 min and re-equilibrated in 98% buffer A for 29 
min. LTQ-Orbitap Velos was used in data dependent mode. A scan cycle comprised 
MS1 scan (m/z range from 335-1800) in the velos orbitrap followed by 15 sequential 
dependant MS2 scans (the threshold value was set at 5000 and the minimum injection 
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time was set at 200 ms) in LTQ with collision induced dissociation. The resolution of 
the Orbitrap Velos was set at to 60,000. To ensure mass accuracy, the mass 
spectrometer was calibrated on the first day that the runs were performed.  
 
2.6.2 Tryptic mass fingerprinting 
 
Coomassie stained SDS-PAGE gels were digested in-gel with Trypsin gold (Promega) 
and analysed by LC-MS/MS.  In-solution digestion of immobilised proteins was also 
performed with trypsin gold and the peptides recovered and analysed by LC-MS/MS.  
LC-MS/MS spectra were acquired on an LTQ Orbitrap XL (Thermo Fisher). 
 
2.6.3 MaxQuant 
 
Data were processed using MaxQuant version 1.3.0.5 which incorporates the 
Andromeda search engine (Cox and Mann, 2008). Proteins were identified by searching 
a protein sequence database containing T. brucei brucei 927 annotated proteins (Version 
7.1, downloaded from TriTrypDB http://www.tritrypdb.org) supplemented with the 
VSG221 sequence and those offrequently observed contaminants (porcine trypsin, 
bovineserum albumin, and human keratins). Search parametersspecified an MS 
tolerance of 10 ppm, an MS/MS toleranceat 0.6 Da, and full trypsin specificity, 
allowing for up to twomissed cleavages. Carbamidomethylation of cysteine was set 
asafixed modification and oxidation of methionines, N-terminalprotein acetylation, 
andN-pyroglutamate were allowed asvariable modifications. SILAC ratioswere 
calculated using only peptides that could be uniquelymapped to a given protein 
group and required a minimum of 2SILAC pairs. The distribution of SILAC was 
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normalized withinMaxQuant at the peptide level so that the median of log2Ratiois 
zero to account for any errors in cell counting. 
 
2.7 Microscopy 
 
2.7.1 Cell fixing, staining and imaging 
 
All solutions used in this protocol were filtered on a 0.2 µm Minisart filtering unit 
(Sartorious). About 2.5x107T. brucei bloodstream form cells at log phase density were 
harvested by centrifugation and washed with cold 1x TDB followed at 600xg, 10 min at 
4°C (4K15 Sigma Centrifuge) and resuspended very gently to reduce cell bursting.  
Gently resuspend in 1ml cold PBS and add an equal volume of 8% PFA at 4°C for 
30min. Place 10 µl of cell culture on the centre of pre-washed coverslip and let air-dry 
in hood at RT. Coverslips was pre-washed in 70% EtOH and air-dried. Wash in PBS+ 
0.05% NaN3 and keep wet at 4°C until needed. To permeabilize, incubate the coverslips 
10 min at RT, shaking in 1 ml of filtered 0.1% TX-100 in PBS (inside the 12-well 
plate). Wash the coverslips once with 1 ml of 1x PBS (filtered) and transfer the 
coverslips on top of parafilm inside a humid chamber. Block 1h at RT with 50µL of 5% 
(w/v) Fish Skin Gelatin (FSG, Sigma G7765-250ml) + 0.05% (w/v) TX-100 + 10% 
normal goat serum in PBS containing 0.05% NaN3 (pre-filtered in 0.2 um). Pipette 
carefully up & down, so that the solution is well distributed. Spin the goat serum 
solution to remove any precipitate before adding to the blocking solution. The goat 
serum was used because the Alexa secondary antibodies have been produced in goat 
and adding it to the blocking buffer should help reduce unspecific signal. Wash 1x 50ul 
of filtered 1% w/v FSG + 0.05% (w/v) TX-100 in PBS containing 0.05% NaN3. Prepare 
the 1st antibody solution by diluting the antibody stock in filtered 1% (w/v) FSG + 
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0.05% (w/v) TX-100 in PBS containing 0.05% NaN3. If using more than one primary 
antibody, dilute them together in the same solution. After the dilution, spin 5 min at 
16,000 xg, 4˚C to remove insoluble materials. Add 50µl/ coverslip of antibody solution 
and pipette very carefully up & down to be sure that the solution is well distributed. 
Incubate 1 hour at RT. Then wash 3x 50µl of filtered 1% w/v FSG + 0.05% TX-100 in 
PBS containing 0.05% NaN3. Prepare and apply 2
nd antibody solution as described for 
the 1st antibody and cover the humid chamber with foil during the incubation (keeping 
light away). Subsequently, wash 3x 50 µl of filtered 1% w/v FSG + 0.05% TX-100 in 
PBS containing 0.05% NaN3. Wash with 2x 50ul of filtered TBS, remove it by 
aspiration. For mounting, take a frosted glass slide and place 4-5µl of Prolong Gold 
onto the glass slide, then aspirate the last wash from the coverslip, and immediately 
place the side containing the cells down, in contact with Prolong Gold. Incubate the 
slides 5-10 min in the dark. Seal the coverslips with nail varnish and store them covered 
in foil in the cold room, until microscope availability 
 
2.8 Sequon specificity studies 
 
2.8.1 TbBipN reporter protein 
 
BipN was PCR amplified by using primers previously published in (Bangs et al., 1996) 
(seen intable 2.1) and cloned into a pLEW82 plasmid. A glycosylation sequon sequence 
with a HA3 tag (ordered from Dundee Cell Products, seen in appendix) was 
subsequently cloned in directly downstream the BipN sequence and the construct was 
transfected into wild type Trypanosoma brucei cells. 
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2.8.2 TbBipN glycan digestion 
 
10 ml of mid log phase (~2x106) cells with overexpressed BipN reporter protein were 
lysed using 40 µl of lysing buffer 1 (section 2.4.5) and heated at 100°C for 10 min 
before being cooled to room temperature and diluted 1:10 in PBS buffer. To 5 ul of 
sample, 7.5 µl of 1x G5 buffer (NEB) and 7.5 µl (37.5 mU) of EndoH was added over 
night for digestion. PNGase F is compatible with the PBS buffer and therefore 5 µl 
sample was mixed with 7.5 µl enzyme (7.5 U) and 7.5 µl H2O for digestion over night.  
 
2.8.3 TbBipN glycosylation sequon specificity 
 
7 µl of 4x loading buffer and 0.5 µl of 1 M DTT respectively 10 % SDS was added to 
the digested samples before heating at 95 °C. Samples were loaded on a 12 % pre-
casted NuPage gel and run until the 37 kDa marker (All blue, Bio Rad) ran off the gel, 
in order to separate the small changes of molecular weight of the reporter protein. 
Subsequently, the gels were transferred to nitrocellulose membrane as described in 
section 2.4.3 and the Western blot was developed according to section 2.4.4. Finally, the 
bands were quantified using Image Studio Lite version 3.1 (LI-COR Biosciences).  
 
2.8.4 T. brucei STT3 models 
 
Models were built using Phyre2 software. The amino acid sequence of TBsTT3A, 
TbSTT3B and TbSTT3C were inserted and the top hit was the crystal structure of C. 
lari (Lizak et al., 2011). The models were visualised in PYMOL. 
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2.8.5 TbSTT3A and TbSTT3B motif logos 
 
The TbSTT3A and TbSTT3B motif logos were generated using Weblogo3. Acceptor 
peptides that exclusively received Man9GlcNAc2 or Man5GlcNAc2 are seen in 
Appendix. 
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3 – Results 
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3.1 Essentiality of TbSTTA - generation of TbSTT3A gene replacement 
mutants 
 
Previous RNAi gene knockdown showed that individual TbSTT3Aor TbSTT3B 
knockdowns (by 80-90%) produced dramatic glycosylation changes but did not affect 
cell viability in culture, whereas simultaneous knockdown of both these genes caused 
cell death (Izquierdo et al., 2009a). Sincethe RNAi knockdown was incomplete,there 
are still questions as to whether TbSTT3A and TbSTT3B might be individually essential 
for cell growth in vitro. Therefore, to continue the work of Izquierdo et al, and seek 
further knowledge concerning the essentiality of TbSTT3A in vitro, gene replacement 
experiments were initiated. The Lister 427 bloodstream form cell line used for all 
genetic modification has been genetically modified to expresses a T7 polymerase and a 
tetracyclin repressor protein (TetR) under neomycin control. These modifications make 
it possible to generate both null and conditional mutations by gene replacement (Wirtz 
et al., 1999). 
 
3.1.1 Introduction of a TbSTT3A ectopic copy 
 
Using the TbSTT3A,B,C+/- heterozygote cell line previously established (Izquierdo et 
al., 2009a), a gene replacement construct was engineered to try to specifically remove 
the last copy of TbSTT3A (data not shown). However, no surviving cells could be 
obtained after transfection and selection, so a new strategy for targeted replacement of 
TbSTT3Awith an antibiotic cassette was designed. We reasoned that, if TbSTT3A is 
essential also in vitro (i.e. in cell culture),an ectopic gene copy expressing sufficient 
levels of the enzyme will be needed to allow replacement of the last endogenous 
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TbSTT3A gene. Therefore, a pLEW100 plasmid containing the TbSTT3A gene 
(previously engineered by Luis Izquierdo) was transfected into the heterozygote cell 
line. This was the first step in trying to create a conditional null mutant. The pLEW100 
plasmid is a dual promoter expression vector which targets the rRNA spacer locus (see 
Figure 3.1.2). The plasmid has a procyclin promotor which is driving expression of the 
TbSTT3A gene through two (for greater efficiency) tetracycline operator sequences. The 
pLEW100 plasmid also contains a T7 promoter which constitutively expresses the 
phleomycin resistance gene (Wirtz et al., 1999). Hence, phleomycin can be used for the 
selection of transfected cells after electroporation. The ectopic copy of TbSTT3A was 
not tagged.  
Subsequent to obtaining recovered cells, the parasites were cloned and genomic DNA 
was extracted to test for the introduction of the TbSTT3A ectopic copy. With the three 
STT3 genes sharing a large percentage of their DNA sequence and also being 
surrounded by identical untranslated region (UTR) repeats, Southern blotting proved to 
be challenging. However, by probing against a stretch of sequence in TbSTT3A(primers 
found in table 2.1) it was possible to verify introduction of the ectopic TbSTT3A copy. 
Genomic DNA from transfected (5 µg) and parental (2 µg) cell lines were digested with 
PstI and BglII. PstI is found upstream of the STT3 locus whereas BglII is found in the 3’ 
end of all three genes. In the pLEW100 plasmid a BglII site is found upstream of 
TbSTT3Aas well as in the C-terminus of the gene.(Figure 3.1.1). 
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Figure 3.1.1. A. Digestion pattern for Southern blot analysis. A schematic showing 
that the probe binds best to a sequence in TbSTT3A (green box) and gives rise to 
bands at 3.6 kb (endogenous TbSTT3A) and 2.4 kb (ectopic TbSTT3A). The probe 
still associates weakly with TbSTT3B and TbSTT3C(green and white striped box), 
providing the 3.3 kbband. B. Southern blot showing the endogenous TbSTT3A,B and 
C genes in the parental TbSTT3A,B,C +/- cell line (lane 1) and the introduction of 
the ectopic copy of TbSTT3A in the TbSTT3A,B,C +/-; TbSTT3A tetracycline-
inducible cell line. 
A 
B 
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The single additional band was of the correct size and confirmed that the ectopic 
TbSTT3A gene had been introduced to the rRNA spacer, establishing the cell line 
illustrated in Figure 3.1.2.  
 
 
 
3.1.2 In situ tagging TbSTT3A with C-terminal YFP-HA3 
 
Following introduction of the ectopic TbSTT3A gene, a strategy for simplifying specific 
gene replacement of TbSTT3A was designed. By in situ tagging the endogenous 
TbSTT3A, unique DNA sequence will be introduced into the otherwise identical UTR 
repeats. This unique sequence can be used to specifically replace the last copy of 
TbSTT3A. The in situtag will also enable immunoprecipitation and immunofluorescence 
experiments with the protein (chapter 3.2). Since the first transmembrane region of 
TbSTT3A act as a signal and anchor sequence that both targets the protein to the ER 
and anchor it to the bilayer, tagging was directed to the C-terminus which points into 
the ER lumen (Kim et al., 2005). pMOTag plasmids are generally used to in situ tag 
protein in T. brucei and were therefore chosen for this purpose. The plasmid series 
includes different tags and selection markers that can be used for tagging endogenous 
Figure 3.1.2.Cell line established by introduction of a tetracycline-inducible ectopic 
copy of TbSTT3A. 
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genes, rendering native expression levels of the tagged proteins (Oberholzer et al., 
2006). The pMOTag4YH introduces an YFP tag followed by an HA3 tag under 
hygromycin (HYG) selection and was used for in situ tagging TbSTT3A. The 3’ end of 
TbSTT3A (without the stop codon) including the stretch of unique sequence was PCR 
amplified together with the 3’ UTR directly downstream of the gene. Both DNA 
products were subsequently cloned into the plasmid (primers found in table 2.1). The 
plasmid was linearized by NotI before being transfected into the previously established 
cell line (Figure 3.1.3).  
 
 
 
The unique sequence found in TbSTT3A should direct the tag to the 3’ end of the gene 
(Figure 3.1.4). However, there was a risk that the 3’ UTR sequence would 
homologously recombine downstream of TbSTT3B. In that case TbSTT3A would be in 
situ tagged simultaneously as the TbSTT3B gets knocked out. 
 
Figure 3.1.3.Strategy for the generation of the pMOTag4YH in situ tagging 
construct. The 3’ end of TbSTT3A and the 3’ UTR was PCR amplified and cloned 
into the pMOTaG4YH plasmid. 
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Since it was not known if the C-terminus tag would interfere with folding and/or 
function of the protein, the expression of the ectopic TbSTT3A was induced by 
supplementation of tetracycline to the media before transfection with the in situ 
construct. After HYG selection, recovered cells were made clonal and the genotype was 
analysed by Southern blotting. When probing against HYG following PstI or PstI/NdeI 
digestion (Figure 3.1.5), specific bands of the correct size were seen, confirming that 
TbSTT3A has been correctly in situ tagged. (Figure 3.1.6). 
 
 
 
Figure 3.1.5.Digestion pattern for Southern blot analysis of in situ tagged TbSTT3A. 
When probing against HYG following PstI digestion, two bands should be 
observable at 1.4 respectively >10 kb. When digesting with PstI and NdeI, three 
bands should be seen at 0.7, 1.4 and 7.0 kb, respectively.  
Figure 3.1.4.Strategy for the in situ tagging of TbSTT3A.The 3’ end of TbSTT3A 
wasfused to an YFP tag followed by a HA3 tag under HYG selection. 
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To further ensure that the in situ tag does not impair protein function of TbSTT3A, two 
additional analyses were carried out. By comparing the growth rate of cells in 
permissive and non-permissive conditions for eleven days it was evident that cells with 
the in situ tagged TbSTT3A gene as the sole source for the protein grew as well as the 
cells with the overexpressor induced (Figure 3.1.7).  
 
Figure 3.1.6.Southern blot visualising in situ tagging of TbSTT3A.Lane 1 and 3: 
Genomic DNA (5 µg) from transfected cells after PstI or PstI/NdeI digestion. Lane 2 
and 4: Genomic DNA (5 µg) from parental cell line after PstI or PstI/NdeI digestion. 
The single PstI digestion resulted in two predicted bands, 1.4 and >10Kb, indicating 
that only one copy has been introduced. The PstI and NdeI double digestion released 
three HYG containing fragments of the predicted sizes 0.7, 1.4 and 7.0 kb. The 7Kb 
band confirmed that the in situ tag has been specifically introduced into the 3’-end of 
the TbSTT3A gene. A HYG probe was used for the analysis. 
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However, since cells were viable during RNAi knock down of TbSTT3A, the function 
of the enzyme was also adressed. By purifying VSGs from cells in non-permissive 
conditions and subsequently digesting with PNGaseF and EndoH, conclusions about the 
glycosylation state could be drawn. The VSG found on parasites used for this thesis are 
of the 221 variant. It contains two N-glycosylation sites, one at Asn263 which is 
occupied by small, biantennary, endoglycosidase-H (EndoH)-resistant paucimannose 
and complex structures, which originate from the TbSTT3A transfer of Man5GlcNAc2 
from the Man5GlcNAc2-PP-Dol precursor, and one at Asn428 occupied by conventional 
EndoH-sensitive triantennary oligomannose structures, which originate from the 
Figure 3.1.7.Growth curve of in situ tagged cells with or without overexpressed 
TbSTT3A from the ectopic copy. Cell numbers were counted in biological triplicates 
for eleven days and cells were split when required. Having in situ tagged TbSTT3A 
as the only source for the enzyme does not affect cell viability significantly. 
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TbSTT3B transfer of Man9GlcNAc2 from Man9GlcNAc2-PP-Dol(Izquierdo et al., 
2009a; Jones et al., 2005; Zamze et al., 1991). Thus, analysis of VSG221 N-
glycosylation allows us to determine whether the biantennary N-glycan is present, 
thereby verifying the function of the in situ tagged TbSTT3A. Cell-surface VSG was 
purified in a soluble form (sVSG221) by osmotic shock, a process that releases sVSG 
from the parasite surface by the action of endogenous GPI-specific phospholipase C 
which cleaves the dimyristoylglycerol lipid component of the VSG GPI anchor(Cross, 
1975a, 1984; Ferguson et al., 1985). This cell surface-derived sVSG221 was subjected 
to both EndoH and PNGaseF digestion and analysed by SDS–PAGE and Coomassie 
blue staining. EndoH cleaves triantennary oligomannose oligosaccharides whereas 
PNGaseF digests oligomannose, hybrid, and complex oligosaccharides (Maley et al., 
1989). These enzyme treatments will result in specific digestion patterns depending on 
the type(s) of glycans that have been transferred to the N-linked glycosylation sequons 
of the sVSG.In Figure 3.1.8, the same reduction in molecular weight is seen after 
EndoH and PNGaseF digestion as compared to a wild type  cell line, showing that the in 
situ tagged TbSTT3A is still able to transfer Man5GlcNAc2 from the Man5GlcNAc2-PP-
Dol precursor to the Asparagine at position 263 under non-permissive conditions. 
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3.1.3 TbSTT3A gene replacement 
 
By in situ tagging TbSTT3A, a unique DNA sequence was introduced to the STT3 
locus. This DNA was used in the attempts to replace TbSTT3A with an antibiotic 
cassette under permissive conditions (Figure 3.1.9).  
 
Figure 3.1.8.SDS-PAGE Coomassie stained gel visualising sVSG from the 
TbSTT3A in situ tagged cell line and a wild type control. EndoH cleaves off 
triantennary oligomannose glycans whereas PNGaseF digests both tri- and 
biantennary glycans. Lane 1: VSG221 from wild type cell line. Lane 3 and 5: 
VSG2212 from wild type cell line after EndoH (3) and PNGaseF (5) treatment. Lane 
2: VSG221 from in situ tagged cell line. Lane 4 and 6: VSG221 from in situ tagged 
cell line after EndoH (4) and PNGaseF treatment.The digestion pattern indicates that 
Man5GlcNAc2 from the Man5GlcNAc2-PP-Dol precursor has been transferred to the 
asparagine at position 263 and, hence, that the function of the tagged TbSTT3A has 
remained unaffected under non-permissive conditions. 
50 kDa 
12 3 4 5 6 
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The approach to create the TbSTT3A replacement construct is described in Figure 
3.1.10. Briefly, about 1000 bp of the 5’ UTR and the flanking YFP were amplified by 
PCR (primers found seen in Table 2.1). The PCR products were joined together by PCR 
and cloned into the pGEM5Zf plasmid via two NotI restriction sites. Subsequently, the 
antibiotic resistance cassette was ligated into the plasmid via BamH and HindIII 
digestion. In a final step, the construct was released from the plasmid by NotI digestion 
and was later used in gene replacement trials. 
 
Figure 3.1.9.Strategy for TbSTT3A gene replacement under permissive conditions. 
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After electroporation, recovered cells were made clonal and DNA was extracted for 
genomic analysis. A large number (20) of clones were initially screened by PCR. By 
using primers that anneal to a sequence outside the gene replacement construct, two 
different fragments could be amplified. If the 0.4 Kb BSD gene has replaced the 2.4 Kb 
TbSTT3A gene, a fragment of ~2 Kb should be observable, compared to a 4 Kb 
fragment if no replacement has occurred. Many (10) clones showed the smaller band, 
indicating that homologous recombination had occurred in the correct place (Figure 
3.1.11). 
 
Figure 3.1.10.Strategy for the generation of TbSTT3A gene replacement construct. 
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Subsequent to the PCR screen, selected clones were followed up by Southern blot to 
verify theTbSTT3A knock out. In this experiment, a promiscuous STT3 probe was used. 
This probe binds an identical sequence found in all three genes, TbSTT3A, TbSTT3B 
andTbSTT3C. By digesting with PstI, BspHI and XhoI four different sized fragments 
should be observable for the parental cell line. However, the 2.7 kb band should be 
absent in the clones if BSD has replaced TbSTT3A (Figure 3.1.12).  
 
Figure 3.1.11.PCR screen of a TbSTT3A KO clone, showing replacement of 
TbSTT3A by BSD. Using primers that anneal outside of the gene replacement 
construct, two possible bands can be amplified. If TbSTT3A is still present, a 4 kb 
and will be amplified. If BSD has replaced TbSTT3A, a 2 kb band will be amplified. 
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Figure 3.1.13 shows that the TbSTT3A band was lost in the knock out clones.However, 
a new band was seen, making interpretation difficult. Insufficient digestion was ruled 
out since the size of the new band could not be produced by the three restriction 
enzymes that were used. Since the ectopic TbSTT3A gene was not visible, questions 
were raised whether the previously introduced inducible ectopic copy of TbSTT3A had 
Figure 3.1.12.Digestion pattern for Southern blot visualising TbSTT3A gene 
replacement. The probe binds an identical sequence found inTbSTT3A, TbSTT3B 
andTbSTT3C. A: By digesting with PstI, BspHI and XhoI four fragments of different 
sizes should be visualised if TbSTT3A is still present). B: The 2.7 kb band should be 
absent if BSD has replaced TbSTT3A. 
A 
B 
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been lost, possibly causing survival pressure to duplicate TbSTT3A in the genome. One 
way to address that question was to repeat the Southern blot with a different probe 
(TbSTT3A specific) and digestion pattern, providing information of fragment size of the 
ectopic TbSTT3A gene. However, the result showed that the inducible ectopic copy of 
TbSTT3A was still present (data not shown).  
 
 
 
Therefore, new gene replacement trials were performed and genomic DNA was 
extracted from clonal cultures and once again screened by PCR. The same forward 
primer was used, however, the reverse primer anneals inside the BSD gene. In this way 
a PCR product of 0.85 kb will only be produced if BSD has replaced TbSTT3A in the 
Figure 3.1.13.Southern blot visualising the loss of TbSTT3A.Lane 1: Genomic DNA 
(5 ug) from transfected cells after PstI, BspHI and XhoI digestion. Lane 2: Genomic 
DNA (5 ug) from parental cell line after PstI, BspHI and XhoI digestion. A 
promiscuous STT3probe binding an identical sequence found inTbSTT3A, TbSTT3B 
andTbSTT3C was used for blotting. TbSTT3A is lacking after gene replacement, in 
agreement with the PCR analysis. However, the ectopic TbSTT3A is not observable 
and a new band at 2.9 kb was seen in the mutant cell line. 
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STT3 locus. Figure 3.1.14 displays a band at 0.85 kb, indicating that TbSTT3A has again 
been replaced.  
 
 
Positive cells were followed up by Southern blot analysis. This time a new digestion 
pattern using a different panel of restriction enzymes (SalI, PstI and BglII) was designed 
for the use with promiscuous TbSTT3 probe (Figure 3.1.15). 
 
Figure 3.1.14.PCR screen of a TbSTT3A KO clone, showing replacement of 
TbSTT3A by BSD. PCR was performed using a forward primer that anneals 
upstream of the gene replacement construct and a reverse primer that anneals inside 
the BSD gene. The band at 0.85 kb indicates that BSD has replaced TbSTT3A in the 
STT3 locus. 
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With these restriction enzymes all the endogenous genes plus the ectopic TbSTT3A were 
visible at the correctly sized fragments with the parental cell line (Figure 3.1.16, lane 1) 
and, once again, loss of TbSTT3A was evident in the knock out clones. (Figure 3.1.16, 
lane 2). Nevertheless, similar to the previous Southern blot, new weak bands were 
Figure 3.1.15.Digestion pattern for Southern blot visualising TbSTT3A gene 
replacement. The probe binds an identical sequence found inTbSTT3A, TbSTT3B 
andTbSTT3C.A:By digesting with SalI, PstI and BglII four fragments of different 
sizes should be visualised if TbSTT3A is still present. B: The 2.9 kb band should be 
absent if BSD has replaced TbSTT3A. 
A 
B 
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visible after gene replacement. This might be an indication of genomic rearrangement 
promoted by survival pressure during gene replacement, which has been published 
previously (Castillo-Acosta et al., 2013). It might be possible that genomic 
rearrangement will promote chimeric genes to retain the TbSTT3A function during gene 
replacement attempts. This could explain the weaker bands seen in lane 2. If the probing 
sequence is rearranged, different sized bands might be seen. Furthermore, less probe 
might bind to a rearranged sequence, yielding weaker bands. 
 
 
 
Figure 3.1.16.Southern blot visualising the loss of TbSTT3A.Lane 1: Genomic DNA 
(5 µg) from parental cell line after SalI, PstI and BglII digestion. Lane 2:Genomic 
DNA (5 µg) from transfected cells after SalI, PstI and BglII digestion. A 
promiscuous STT3probe binding an identical sequence found inTbSTT3A, TbSTT3B 
andTbSTT3C was used for blotting. TbSTT3A is missing after gene replacement, in 
agreement with the PCR analysis and previous Southern blot analysis. The ectopic 
TbSTT3A is seen at 2.4 kb. However, two new weak bands were seen after TbSTT3A 
gene replacement, at 1.2 and 4.5 kb. 
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As seen in Figure 3.1.17, the mutant cells showed no growth phenotype. To analyse if 
TbSTT3A function was still present, soluble VSGs from cells growing without 
tetracycline were again assessed by EndoH and PNGaseF digestion and analysed by 
SDS–PAGE and Coomassie blue staining (Figure 3.1.18).  
 
 
 
Figure 3.1.17.TbSTT3A mutant cells show no growth phenotype in culture. Cell 
numbers were counted in triplicate for eight days and cells were split when required. 
Cells grown in permissive and non-permissive conditions are seen in blue and red, 
respectively. 
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The weight reduction seen after PNGaseF digestion indicates that a biantennary glycan 
has been cleaved suggesting Man5GlcNAc2is still being transferred from the 
Man5GlcNAc2-PP-Dol precursor to the asparagine at position 263. Therefore, 
altogether, the data suggest that the mutant cell line is not a TbSTT3A conditional null. 
Instead, it is likely that the function of TbSTT3A was preserved by genomic 
rearrangement in order to sustain cell growth during gene replacement, even in the 
presence of an expressed ectopic copy of the gene. This suggests that TbSTT3A is 
essential in vitro, though clearly further work is required to understand the putative 
genomic rearrangements that occur on trying to replace the second TbSTT3A allele. 
 
 
 
Figure 3.1.18.SDS-PAGE Coomassie stained gel visualising sVSG from the 
TbSTT3A gene replacement cell line and a wild type control. EndoH cleaves 
triantennary glycans whereas PNGaseF digests both tri- and biantennary glycans. 
Lane 1-3: VSG221 from wild type cell line after no (1), EndoH (2) or PNGaseF (3) 
treatment. Lane 4-6: VSG221 from in situ tagged cell line after no (1), EndoH (2) or 
PNGaseF (3) treatment. The digestion pattern indicates that Man5GlcNAc2 from the 
Man5GlcNAc2-PP-Dol precursor has been transferred to the asparagine at position 
263 and, hence, that the function ofTbSTT3A is still present. 
50 kDa 
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3.1.4 Localisation studies of TbSTT3A 
 
OST has previously been shown to interact with other ER membrane proteins (Wilson 
et al., 2005)and therefore theT. brucei enzyme has been presumed to also be integrated 
in the ER membrane. However, to date, no experimental data has demonstrated this. In 
order to investigate if TbSTT3A could be localised in T. brucei, experiments were 
performed with the TbSTT3A-YFP-HA3 tagged cell line. 
The genetically modified cells were prepared according to the protocol provided in 
Materials and Methods. Briefly, the cells were fixed in 4 % paraformaldehyde and 
plated on coverslips followed by washing, permeabilization and blocking. 
Subsequently, the coverslips were incubated with anti-Bip (ER marker) together with 
either anti-GFP or anti-HA (Table 3.1.1) and washed before microscopy analysis was 
performed. The results are seen in Figure 3.1.19. 
 
Table 3.1.1.List of antibody combinations used for the TbSTT3A-YFP-HA3 localisation 
studies. 
Antibody combination Dilution 
α-GFP/α-Bip 1:400/1:2000 
α-GFP/α-Bip 1:400/1:1000 
α-GFP/α-Bip 1:300/1:2000 
α-GFP/α-Bip 1:300/1:1000 
α-HA/α-Bip 1:290/1:2000 
α-HA/α-Bip 1:290/1:1000 
α-HA/α-Bip 1:580/1:2000 
α-HA/α-Bip 1:580/1:1000 
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Of the antibody combinations seen in Table 3.1.1, the one that showed the best results 
was anti-Bip and anti-HA with 1:2000 and 1:580 dilutions. It was not surprising that the 
anti-GFP gave no positive results since the tagged TbSTT3A was not detected using this 
antibody for Western blotting. The signal for both TbBip and the in situ tagged 
TbSTT3A was weak and further improvements will have to be carried out, nonetheless, 
TbSTT3A-YFP-HA3 seems to co-localise with TbBip in Figure 3.19 (A, B and C). In A, 
one can see TbSTT3A highlighting the perinuclear ring, indicative of ER localisation.  
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The weak signal for TbBip can possibly be explained by an old aliquot of the antibody. 
The similarly weak signal for TbSTT3A-YFP-HA3 might be due to low abundance of 
the proteinin combination with the large size of the ER. However, the results seen in 
Figure 3.19 suggested that TbSTT3A-YFP-HA3 co-localises with TbBip. More 
optimisation will be needed to obtain clearer data proving that the in situ tagged 
TbSTT3A is localised in the ER membrane in T. brucei. 
 
A 
B 
C 
D 
Figure 3.1.19. Localisation studies of TbSTT3A-YFP-HA3. Cells were stained with 
Dapi (blue channel), α-Bip and Alexa 488-conjugated anti-mouse antibody (green 
channel) and α-HA and Alexa 594-conjugated anti-rabbit antibody (red channel). 
Although the images were not optimal, co-localisation of ER membrane protein 
TbBip and the YFP-HA3 tagged TbSTT3A was observed in A, B and C. In D, a 
negative control using no primary antibodies (α-Bip and α-HA) gives no signal. 
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3.2 The search for novel TbSTT3A binding partners 
 
Compared to the multiprotein complexes in higher eukaryotes, T. brucei 
oligosaccharyltransferase (OST) is suggested to comprise a single protein, the catalytic 
subunit STT3. This hypothesis originatedbecause no homologues were found in 
bioinformatic searches of the T. bruceigenome, indicating that it lacks all OST subunit 
homologues except for the catalytic STT3 subunit, for which there are three complete 
paralogous genes. (Berriman, 2005; Izquierdo et al., 2009a). However, it has been 
shown before, for example for the GPI biosynthetic machinery that, in some cases 
structural (but not sequence) homology can exist (Nagamune et al., 2003). To 
investigate if the oligosaccharyltransferase in T. brucei has any such structural 
homologue subunits and/or novel binding partners, immunoprecipitation and blue native 
gel electrophoresis experiments were performed using in situ tagged TbSTT3A. 
 
3.2.1 TbSTT3A-YFP-HA3 immunoprecipitation 
 
Thein situ tag introduced in the previous chapter was meant to enable 
immunolocalisation studies and facilitate pull-down experiments to investigate potential 
TbSTT3A binding partners. The C-terminal tag consists of a eukaryotic YFP followed 
by a three hemagglutinin (HA3) epitopes. In between the two tags, a TEV site was 
introduced using the primers found in Table 2.1. To detect the tagged TbSTT3A by 
Western blotting, 1*109 cells were lysed before immunoprecipitation with either anti-
GFP or anti-HA according to the protocol in section 2.4.5 of Materials and Methods. 
Membrane proteins are known to be challenging to pull down and heating to 100 °C has 
been suggested to promote aggregation. To test this, cells were lysed in 1 % SDS in the 
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presence of 0.1 M DTT and protease inhibitors, followed by heating up to 100 °Cor 50 
°C for 10 minutes. The lysates were subsequently diluted to 0.03 % SDS to facilitate 
immunoprecipitation. Figure 3.2.1 shows that TbSTT3A was detected after anti-HA pull 
down following heating to both 50 °Cand 100 °C (lane 1 and 2). However, TbSTT3A 
was not detected after immunoprecipitation by anti-GFP antibodies (lane 4 and 5). A 
wild-type cell line was used as a negative control (lane 3 and 6).  
 
 
 
Figure 3.2.1.Western blot results after anti-HA and anti-GFP immunoprecipitation. 
Lane 1 and 2: Anti-HA immunoprecipitation and detection after heating to 50°C 
(lane 1) or 100 °C (lane 2) during cell lysis. TbSTT3A-YFP-HA3 is detected at 
approximately 95 kDa. Lane 4 and 5: Anti-GFP immunoprecipitation and detection 
after heating to 50°C (lane 4) or 100 °C (lane 5) during cell lysis. The tagged 
TbSTT3A was not detectable when using anti-GFP. In lane 3 and 6, a wild-type cell 
line was used as a negative control, lysed at 100 °C and detected by anti-HA (lane 3) 
or anti-GFP (lane 6). 
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Using anti-HA antibody for both immunoprecipitation and detection, the tagged 
TbSTT3A-YFP-HA3 fusion protein was detected at approximately 95 kDa. The 
theoretical molecular weight for YFP and HA3 tagged TbSTT3A is 117 kDa and the 
smaller molecular weight detected is in agreement with previously published results 
(Izquierdo et al., 2009a) where untagged TbSTT3A was detected at a molecular weight 
at about 70 kDa (theoretical molecular weight 89 kDa). Since the tagged TbSTT3A was 
not detectable by anti-GFP immunoprecipitation, concerns were raised about the YFP 
tag. In YFP, a threonine has been mutated into a tryptophan compared to the GFP tag, 
and GFP antibodies should still be able to bind YFP. Furthermore, since the HA3 tag is 
found downstream of the YFP, no nonsense or stop codon mutation can have occurred. 
Additionally, since the proteins are denatured prior to Western blotting, YFP misfolding 
should not be a major issue. Therefore, we assumed that anti-GFP immunoprecipitation 
of TbSTT3A was below the detection limit when starting with 1*109 cells. Since the 
HA3 epitope functioned well when used to pull down TbSTT3A we decided to remove 
the YFP tag. This should also improve the chances of detecting potential binding 
partners since the 27 kDa YFP tag might have blocked potential interactions. 
 
3.2.2 In situ tagging TbSTT3A with HA3 
 
Similarly to the previous in situ tagging strategy of TbSTT3A, the C-terminus of the 
gene (excluding the stop codon) and the 3’ UTR directly downstream of TbSTT3A were 
cloned into the pMOTag4H plasmid (Figure 3.2.2). This plasmid only introduces a HA3 
tag, which was directed to the C-terminus, under HYG selection. 
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The plasmid was linearized before being transfected into the TbSTT3A,B,C +/- cell line. 
No overexpressing ectopic copy was needed during electroporation since previous data 
suggested that these tags do not interfere with the function of the protein. The HA3 
epitope will fuse to the C-terminus of TbSTT3A through homologous recombination 
(Figure 3.2.3) and cells were subsequently selected by adding HYG to the media. 
 
 
 
Following transfection, recovered cells were made clonal and the genotype was 
analysed by Southern blotting. When probing against HYG following PstI digestion 
Figure 3.2.3.Strategy for the HA3in situ tagging of TbSTT3A.The C-terminus of 
TbSTT3A will befused to an HA3 tag under HYG selection. The tag was introduced 
to the TbSTT3A,B,C +/- heterozygote cell line. 
Figure 3.2.2.Strategy for the generation of the pMOTag4H in situ tagging construct. 
The C-terminus of TbSTT3A and the 3’ UTR was PCR amplified and cloned into the 
pMOTaG4H plasmid. 
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(Figure 3.2.4), specific bands of the correct size were seen, confirming that TbSTT3A 
has been correctly in situ tagged with an HA3 epitope (Figure 3.2.5). 
 
 
 
 
 
 
The TbSTT3A-HA3 cell line showed no growth phenotype (data not shown). To verify 
that the enzyme function was not impaired by the tag, sVSG was purified and N-glycans 
Figure 3.2.5.Southern blot visualising HA3in situ tagging of TbSTT3A.Lane 1: 
Genomic DNA (5 µg) from transfected cells after PstI digestion. Lane 2: Genomic 
DNA (5 µg) from parental cell line after PstI digestion. The PstI digestion resulted in 
two predicted bands, 4.6 and >10Kb, indicating that only TbSTT3A has been in situ 
tagged. A HYG probe was used for the analysis. 
Figure 3.2.4.Predicted digestion pattern for Southern blot analysis of in situ tagged 
TbSTT3A. When probing against HYG following PstI digestion, two bands should be 
observable at 4.6 and >10 kb. 
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were digested with EndoH and PNGaseF, as described in Material and Methods (and 
briefly in section 3.1.2). In Figure 3.2.6, the same reduction in molecular weight was 
seen after EndoH and PNGaseF digestion as compared to a wild-type cell line, 
confirming that the TbSTT3A-HA3 is still able to transfer Man5GlcNAc2and that the 
functions have remained intact during in situ tagging. 
 
 
 
3.2.3 TbSTT3A-HA3 immunoprecipitation under stringent conditions 
 
After verifying that TbSTT3A had been correctly tagged with an HA3 epitope and that 
function was conserved, new attempts to immunoprecipitate the protein were initiated. 
With the new TbSTT3A-HA3 cell line, the protein was detected after direct Western 
blotting, loading the cell equivalent of 5*106 cells on the gel (data not shown). 
Visualised in Figure 3.2.7 are the Western blot and Coomassie stained gel after pulling 
down TbSTT3A with an anti-HA antibody under stringent conditions, as described in 
Figure 3.2.6.SDS-PAGE Coomassie stained gel visualising sVSG from the 
pMOTag4H transfected TbSTT3A-HA3in situ tagged cell line and a wild-type 
control. EndoH cleaves off triantennary glycans whereas PNGaseF digests both tri- 
and biantennary glycans. The digestion pattern indicates that Man5GlcNAc2 from the 
Man5GlcNAc2-PP-Dol precursor has been transferred to the asparagine at position 
263 and, hence, that the function of the tagged TbSTT3A was unaffected. 
    1          2          3       4         5         6 
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section 2.4.5. Briefly, 5*108 cells were lysed at 100 °C in 1 % SDS and 0.1 M DTT in 
the presence of protease inhibitors and the lysate was later diluted to 0.03 % SDS before 
being incubated with anti-HA mouse antibody. Finally, magnetic beads binding the 
antibodies were added and subsequently captured with a magnet and washed 
extensively. Bound proteins were then eluted before being loaded on a gel. After 
Western blotting with anti-HA, TbSTT3A was detected at just below 75 kDa in the 
TbSTT3A-HA3 cell lysate (lane 1). No band was seen at the same molecular weight 
when using a wild-type cell lysate as a negative control. Lanes 3 and 4 show the same 
two cell lysates (TbSTT3A-HA3 and wild-type) separated on a gel and Coomassie 
stained. Loading appeared equal and the bands seen at 25 and 50 kDa are the light and 
heavy chain of the mouse anti-HA used in the pull downs. The secondary anti-mouse 
antibody detects both these IgG fragments and potential anti-HA mouse antibodies 
bound to HA epitopes.  
 
 
Figure 3.2.7.(Next page) Western blotted and Coomassie stained gels after 
separation of cell lysate from TbSTT3A-HA3 and wild-type cell lines. Lanes 1 and 2 
show TbSTT3A-HA3 and wild-type lysate following Western blotting using an anti-
HA antibody. TbSTT3A is detected below 75 kDa in lane 1, however, a band at the 
same molecular weight was not seen in the wild-type sample shown in lane 2. Lanes 
3 and 4 show the same cell line lysates with Coomassie staining. No band was seen 
at the same molecular weight in the control shown in lane 4. Bands seen at 25 and 50 
kDa in all lanes are the light and the heavy chain of the antibody used in the 
immunoprecipitation. 
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3.2.4 Optimising mild detergent conditions for immunoprecipitation 
 
Following the pull down of TbSTT3A in stringent conditions, the next step was 
immunoprecipitation of the protein in a native state, facilitating the search for potential 
binding partners. Digitonin is a detergent that effectively solubilises lipids and hence a 
common choice for immunoprecipitation of membrane proteins. Most published data on 
solubilising membrane proteins for pull down uses 1 % digitonin during cell lysis 
(Oeljeklaus et al., 2012; Roboti and High, 2012b; Singha et al., 2012). To analyse how 
the concentration of digitonin affects interacting proteins, a test experiment was set up 
using VSG221 as a reporter protein. Native VSG is a homodimer with a molecular 
weight of approximately 100 kDa (Cross, 1975b). The VSGs were diluted in 1.0, 0.8, 
0.6, 0.4, 0.2 and 0.0 % digitonin before being loaded on a blue native gel (Materials and 
Methods, 2.4.7) As seen in Figure 3.2.8, the VSG dimer (100 kDa) is the dominant form 
when using 0, 0.2 and 0.4 % digitonin. By diluting the dimer in 0.6% digitonin, half of 
the dimers disassociated into their monomeric state (50 kDa). When using even higher 
concentrations of digitonin the monomeric state is the predominant one seen. 
Figure 3.2.7 
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3.2.5 TbSTT3A-HA3 immunoprecipitation under mild conditions 
 
After showing that use of more than 0.8% digitonin significantly disrupted the VSG 
dimer, we decided to test lysing T. brucei cells in 0.5 % digitonin (described in section 
2.4.5). Briefly, 5*108 cells were lysed in 0.5 % digitonin on ice for 30 minutes, followed 
by incubating the cell lysate with anti-HA mouse antibody. Magnetic beads, which will 
bind to the antibodies, were subsequently added and following capture of the magnetic 
beads, samples were washed and the bound proteins were eluted. The samples were 
subsequently loaded on a gel and Western blotted using a rabbit anti-HA antibody. The 
results are seen in Figure 3.2.9. TbSTT3A was detected at just below 75 kDa, in 
agreement with the pull down in stringent conditions. No bands were visible in the wild-
type sample. Below the Western blot, a Ponceau S stained loading control verifies that 
the samples were equally loaded. 
Figure 3.2.8.Blue native gel showing the quaternary structure of VSG after being 
diluted in different concentrations of digitonin. When no digitonin detergent is added 
or when diluting to 0.2 or 0.4 %, the dimer is the major structural state. When 
diluting to 0.8 or 1.0 % digitonin, the monomeric state was predominant. The same 
amount of dimer and monomer is detected after diluting VSG in 0.6 % digitonin. 
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3.2.6 TbSTT3A-HA3 blue native gel electrophoresis 
 
Previous results had shown that TbSTT3A could be detected at ~70 kDa by Western 
blotting following immunoprecipitation with anti-HA antibody in both stringent and 
mild lysing conditions. As a first step to experimentally investigatingwhetherTbSTT3A 
has any novel binding partners, blue native gel electrophoresis analysis was performed 
with the TbSTT3A-HA3 cell line. Cells were lysed in 0.5 % digitonin for 30 minutes on 
ice before being loaded on a NativePAGE (Invitrogen) gel and finally blotted on a 
PVDF membrane. Anti-HA antibody was used for detection. In Figure 3.2.10, it is clear 
that no band is visible at approximately 75 kDa as had been seen under reducing 
Figure 3.2.9.Western blot result after immunoprecipitation of TbSTT3A-HA3 from 
digitonin lysate.Lane 1: Cell lysate from wild-type cells. Lane 2: Cell lysate from 
TbSTT3A-HA3 cells. TbSTT3A was detected at ~70 kDa in lane 2. A Ponceau S 
stained loading control is seen under the Western blot. 
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conditions. However, a big smear, seen only in the TbSTT3A-HA3 cell line in lane 2 
was detected between 700 and 1200 kDa, suggesting that TbSTT3A might be in a large 
complex. 
 
 
3.2.7 TbSTT3A-HA3 SILAC immunoprecipitation 
 
Since the results from the blue native gel electrophoresis suggested TbSTT3A to be in a 
large complex, we decided to carry out immunoprecipitation experiments using stable 
isotope labelling in cell culture (SILAC, section 2.5). By doing this, we should be able 
to distinguish genuine TbSTT3A binding partners from contaminants according to 
peptide isotopic signatures. For the experiment, wild-type and transgenic parasites 
expressing TbSTT3A-HA3 were grown in parallel and under identical conditions for 
eight cell divisions. However, the transgenic TbSTT3A-HA3 cell line was grown in 
Figure 3.2.10.Western blot results after running blue native gel with TbSTT3A-HA3 
and wild-type cell lysates. Lane 1: No band is seen when using wild-type cell lysate. 
Lane 2: A big smear is detected between 700 and 1200 kDa when using TbSTT3A-
HA3 cell lysate. 
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“heavy medium” containing stable isotope-labelled Lys and Arg (R6K4), whereas the 
wild-type cells were grown in “light medium” containing unlabelled Lys and Arg 
(R0K0). The transgenic TbSTT3A-HA3 parasites and the wild-type cells were harvested, 
washed, counted, mixed together in a 1:1 ratio, and lysed in 0.5 % digitonin. These 
lysates, containing equal amounts of steady-state labelled and unlabelled proteins, were 
used to capture the heavy-labelled TbSTT3A-HA3 proteins on anti-HA magnetic beads 
for proteomic analysis. In this manner, specifically enriched TbSTT3A-HA3 proteins 
and potential associated proteins can be distinguished from nonspecific contaminant 
proteins by the isotope ratios of their tryptic peptides. Thus, TbSTT3A-HA3 and true 
associated protein peptides will have high heavy/light isotope ratios, whereas 
contaminant proteins will have heavy/light isotope ratios close to 1 (Figure 3.2.11). 
 
 
Figure 3.2.11.Overview of the SILAC immunoprecipitation experiment. Wild-type 
bloodstream form cells were grown in light (R0K0) medium, and cells expressing 
TbSTT3A-HA3 were labelled with heavy (R6K4) Lys and Arg. The cells were mixed 
1:1 and TbSTT3A-HA3 was enriched by affinity-selection on anti-HA magnetic 
beads. Peptides from TbSTT3A-HA3 and genuine binding proteins have high 
heavy/light isotope ratios, whereas those from contaminants have ratios close to 1:1. 
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The data set from the experiment was used to search a T. brucei predicted protein 
database using MaxQuant software. Each protein identification was displayed on a plot 
(Figure 3.2.12) of the Log10 value of the intensities of the unique peptides of that 
protein (y axis) and the Log2 value of the heavy to light isotope ratios of the same 
peptides (x axis).  
TbSTT3A (bait) had the highest heavy/light ratio (14.6) closely followed by TbSTT3B 
(9.6) (Table 3.2.1). After these two proteins, the ratio drops to around 1.5. Even though 
a few of these proteins had been significantly enriched (Figure 3.2.12), none of them 
were localised in the ER and were thus categorised as possible contaminants. 
Conclusively, TbSTT3A and TbSTT3B were highly enriched (Figure 3.2.12) compared 
to the rest of the proteins detected in the experiment, suggesting that TbSTT3A and 
TbSTT3B form an oligosaccharyltransferase complex with no other subunits in T. 
brucei. 
 
Table 3.2.1. Top five hits in the TbSTT3A-HA3 SILAC IP. 
Protein ID Description Intensity Heavy/light norm. 
Tb927.5.890 TbSTT3A 
oligosaccharyltransferase 
38682000 14.6 
Tb927.5.900 TbSTT3B 
oligosaccharyltransferase 
8866190 9.6 
Tb927.10.4560 Elongation factor 2 469935 1.4 
Tb927.10.14140 Pyruvate kinase 1 (PYK1) 369950 1.3 
Tb927.8.3530 Glycerol-3-phosphate 
dehydrogenase [NAD] 
1918180 1.3 
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3.2.8 In situ tagging TbSTT3B with MYC3 
 
The result from the SILAC immunoprecipitation experiment suggested that TbSTT3A is 
in a complex with TbSTT3B and that no other novel subunits are part of the T. brucei 
oligosaccharyltransferase. To address this hypothesis, we wanted to in situ tag 
TbSTT3B with a MYC3 epitope, followed by pull-out experiments of the tagged 
protein. By doing this we should be able to detect TbSTT3A when pulling down 
Figure 3.2.12.Plot of the TbSTT3A-HA3 immunoprecipitation proteomics data. 
Each protein identification is represented by a point plotted as the Log2 of their 
heavy-to-light isotope ratio (x axis) versus the Log10 value of the intensities of the 
peptides belonging to each protein (y axis). The black curves represent three 
standard deviations from the mean. Proteins plotted in orangehave a heavy-to-
lightratio above the sigma 3 cut off and are significantly enriched. TbSTT3A (bait) 
and TbSTT3B (annutated) were shown to be highly enriched and are highlighted in 
red. 
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TbSTT3B (and vice versa) by Western blotting. Furthermore, by performing pull-out 
experiment using anti-MYC both TbSTT3B (bait) and TbSTT3A should be enriched. 
TbSTT3B was in situ tagged as previously described. However, the in TbSTT3B situ 
tagging construct (called pMOTag4M*) was ordered from Genescript (Appendix). The 
construct incorporates a MYC3 tag under blasticidin (BSD) selection and was designed 
to contain ~1000 bp of the C-teminus of the TbSTT3B and the 3’ UTR downstream of 
the gene (Figure 3.2.13). The C-terminus of TbSTT3B is highly similar to the one of 
TbSTT3C, but since the 3’ UTR is only found downstream of TbSTT3A and TbSTT3B, 
the tag should only fuse to the C-terminus of TbSTT3B.  
 
 
 
The plasmid was transfected into the TbSTT3A,B,C +/- ; TbSTT3A-HA3 cell line. The 
MYC3 epitope should fuse to the C-terminus of TbSTT3B through homologous 
recombination (Figure 3.2.14) and cells were subsequently selected by adding BSD to 
the media. 
 
Figure 3.2.13.Schematic diagram of the pMOTag4M* construct that was ordered 
from Genescript to facilitate in situ tagging of TbSTT3B. The construct will 
specifically tag endogenous TbSTT3B with a MYC3 epitope under BSD selection. 
97 
 
  
 
Following transfection, recovered cells were made clonal and tagged TbSTT3B was 
detected at the correct molecular weight by Western blot after anti-MYC 
immunoprecipitation in stringent conditions (data not shown), confirming that the cell 
line illustrated in Figure 3.2.15 had been established. 
 
 
 
 
 
Figure 3.2.15.Doubly in situ tagged cell line established after electroporating the 
pMOTag4M* construct and selecting clonal cells with BSD. 
Figure 3.2.14.Strategy for the MYC3in situ tagging of TbSTT3B.The C-terminus of 
TbSTT3B will befused to an MYC3 tag under BSD selection. The tag was introduced 
to the TbSTT3A,B,C +/- ; TbSTT3A-HA3 cell line. 
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3.2.9 TbSTT3B-MYC3 and TbSTT3A-HA3 co-immunoprecipitation under mild 
conditions 
 
5*108 cells from the abovementioned cell line were harvested, washed and lysed in 0.5 
% digitonin. TbSTT3A-HA3 or TbSTT3B-MYC3 were captured from the lysate using 
anti-HA or anti-MYC magnetic beads and subsequently the tagged proteins were 
detected by Western blotting using anti-HA or anti-MYC antibodies. Figure 3.2.16 
visualises the results from the immunoprecipitations. Lane 1 to 4 are the results 
following anti-HA (lane 1 and 2) and anti-MYC (lane 3 and 4) pull down and anti-HA 
detection. The band seen just below the 75 kDa marker in lane 2 is TbSTT3A-HA3 after 
anti-HA immunoprecipitation, verifying that the HA tagged protein has been pulled out 
from the lysate of the transgenic TbSTT3A-HA3/TbSTT3B-MYC3 cell line but not from 
wild-type cell lysate (lane 1). A weak band of the same size is seen in lane 4. This 
suggests that TbSTT3A-HA3 has been co-immunoprecipitated with the MYC tagged 
TbSTT3B and been detected by the anti-HA used for Western blotting. No band at the 
same molecular weight was detected in the wild-type control in lane 3. Lane 5 to 8 are 
the results following anti-HA (lane 5 and 6) and anti-MYC (lane 7 and 8) pull down and 
anti-MYC detection. The band seen just belowthe 75 kDa marker in lane 8 is TbSTT3B-
MYC3 after anti-MYC immunoprecipitation, verifying that the MYC tagged protein has 
been pulled out from the lysate of the transgenic TbSTT3A-HA3/TbSTT3B-MYC3 cell 
line but not from wild-type cell lysate (lane 7). A band of the same molecular weight is 
seen in lane 6. This suggests that TbSTT3A-MYC3 has been co-immunoprecipitated 
with the HA tagged TbSTT3A and been detected by the anti-MYC used for Western 
blotting. No band at the same molecular weight was detected in the wild-type control in 
lane 5. These results are in agreement with the SILAC TbSTT3A pull down, suggesting 
that TbSTT3A and TbSTT3B form an oligosaccharyltransferase complex in T. brucei. 
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Taken together, these data suggest that no novel subunits take part in T. brucei OST. 
However, TbSTT3A appears to be bound to TbSTT3B in the native state, thus forming a 
large multimeric OST complex together. To our knowledge, this is the first time these 
two catalytic subunits have been suggested to be in a complex with each other.  
Figure 3.2.16. Western blot results after anti-HA and anti-MYC pull down. Anti-HA 
was used for detection of TbSTT3A-HA3 in lane 1-4, whereas anti-MYC was used 
for detection of TBSTT3B-MYC3 in lane 5-8. Highlighted in red boxes are bands 
visualising TbSTT3A-HA3 and TbSTT3B-MYC3 (lane 2 and 4 and lane 6 and 8, 
respectively). No bands were detected after using wild-type cell lysate for 
immunoprecipitation (lane 1, 3, 5 and 7). The weak band seen highlighted in lane 4 
following anti-MYC pull down confirms that some TbSTT3A-HA3 co-
immunoprecipitate with the MYC tagged TbSTT3B. The band highlighted in lane 6 
following anti-HA pull down confirms that some TbSTT3B-MYC3 co-
immunoprecipitate with the HA tagged TbSTT3A. The Ponceau S stained membrane 
confirms equal loading. 
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3.3 Acceptor peptide specificity of TbSTT3A and TbSTT3B 
 
In 2005 Jones et al reported that T. brucei uses two precursor N-glycans, Man5GlcNAc2 
and Man9GlcNAc2,unlike the single Glc3Man9GlcNAc2 precursor used under normal 
conditions in most other eukaryotes(Jones et al., 2005). TbSTT3A is responsible for co-
translational transfer of the biantennary Man5GlcNAc2 to specific N-glycosylation 
sequons, whereas TbSTT3B catalyses post-translational transfer of triantennary 
Man9GlcNAc2 to the remaining sterically accessible sequons(Izquierdo et al., 2009a). 
Through proteomic and bioinformatic studies, Izquierdo et al. also proposed that 
Man5GlcNAc2 is transferred to sequons in an acidic environment while Man9GlcNAc2 
is transferred to remaining sequons in both neutral and basic amino acid 
surroundings(Izquierdo et al., 2009a). To improve our understanding of the acceptor 
peptide specificity in T. brucei, an in vivo assay was established. Using a glycosylation 
reporter protein, we could assess what type(s) of glycan(s) had been attached to a single 
N-linked glycosylation sequon on the protein, and thus elucidate which enzyme 
transferred that glycan, TbSTT3A or TbSTT3B (or both). Furthermore, the in vivo assay 
highlighted how the amino acids surrounding the sequon may affect 
oligosaccharyltransferase specificity in T. brucei.  
 
3.3.1 Generation of TbBipN N-linked glycosylation reporter protein 
 
To establish an in vivo assay that could assess whether a biantennary Man5GlcNAc2 or a 
triantennary Man9GlcNAc2 glycan had been transferred by TbSTT3A or TbSTT3B to an 
N-linked glycosylation sequon, a reporter protein with a single N-X-S/T site was 
needed. By removing the ER retention sequon of ER membrane protein TbBip, the 
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smaller protein, TbBipN, is transferred through the secretory pathway and 
secreted(Bangs et al., 1996). TbBipN has no native N-linked glycosylation sequon, 
enabling introduction of a single known sequon, so this protein was chosen to be our 
glycosylation reporter. The TbBipN protein coding DNA sequence was PCR amplified 
using previously published primers (Bangs et al., 1996) and subsequently cloned into a 
pLEW82 plasmid. The pLEW82 plasmid is a tetracycline-inducible high expression 
plasmid but with poor regulation. A single T7 promoter drives the expression of both 
the gene of interest and a phleomycin resistance gene. In addition, the plasmid has one 
tetracycline operator for regulation of the expression and two T7 terminators to prevent 
any T7 polymerase read-through of downstream genes.  
The construct encodes the TbBipN protein fused to the amino acid sequence 
PRAAAXXXXXNATXXXXXQLAAA, followed by three HA tag sequences to 
facilitate Western blotting (Figure 3.3.1, A). The glycosylation sequon, NAT, is flanked 
by five variable amino acids on either side (X) and the PR and QL (proline/arginine and 
glutamine/leucine) amino acids are encoded by the AvrII and MfeI restriction sites that 
are used to introduce different experimental XXXXXNATXXXXX sequences. The two 
AAA sequences (underlined) provide neutral linker sequences beyond the two 
experimentally variable sequences(XXXXX). This construct is incorporated into the 
rRNA spacer and following pheomycin selection, TbBipN will be expressed with either 
a biantennary paucimannose glycan (transferred by TbSTT3A) or a triantennary 
oligomannose glycan (transferred by TbSTT3B) (Figure 3.3.1, B). It is also possible that 
both of these glycans can be transferred to the aspargine in the N-X-S/T sequon. 
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After transfection of wild-type parasites, selected phleomycin resistant cells were lysed 
and the lysate was loaded on a SDS-PAGE gel and subsequently Western blotted using 
anti-HA (green channel) antibodies(Figure 3.3.2).  
Figure 3.3.1.Glycosylation reporterconstruct. The pLEW82 plasmid drives 
expression of both the BipN fusion protein and the phleomycin resistance gene via a 
T7 promotor. The plasmid is tetracycline-inducible and has one tetracycline operator 
and two T7 terminators. TbBipN (blue) is fused to anNAT sequon flanked by five 
variable residues (purple) followed by Ala linker regions (green), AvrII and MfeI 
restriction sites (pink) and an HA3 epitope tag (red). When TbBipN is expressed, the 
protein can carry a biantennary paucimannose or complex glycan transferred by 
TbSTT3A or a triantennary oligomannose glycan transferred by TbSTT3B. It is also 
possible that both types of glycan can be transferred to the asparagine in the N-X-
S/T sequon. 
A 
B 
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Protein equivalent to 2, 4, 8 and 16*105 cells were loaded in lane 1, 2, 3 and 4 and 
TbBipN was detected at approximately 55 kDa in each lane.  
 
 
3.3.2 Establishing an in vivo N-linked glycosylation assay 
 
The first experimental sequon introduced was TEGLLNATDEIAL. This sequence is 
found in VSG MITat.1.8 and is known to receive the biantennary Man5GlcNAc2 from 
TbSTT3A (Mehlert et al., 2010). The isoelectric point of the sequence is 3.42, thus 
fitting with the hypothesis that sequons in an acidic environment receive Man5GlcNAc2. 
To be able to visualise that the asparagine of the sequon had received a biantennary 
Man5GlcNAc2 from TbSTT3A, the cell lysate was treated with EndoH and PNGaseF 
before being loaded on a SDS-PAGE gel and Western blotted using anti-HA (section 
2.8.2). Briefly, cells were lysed in 1 % SDS and 0.1 M DTT in the presence of protease 
inhibitors followed by dilution with Tx100 to 0.03 % SDS to facilitate adequate glycan 
digestion. The lysate was incubated overnight with either EndoH or PNGaseF. EndoH 
cleaves triantennary oligomannose glycans, leaving one GlcNAc residue still bound to 
the asparagine. PNGaseF is an amidase that cleaves between the innermost GlcNAc of 
Figure 3.3.2.Western blot results after anti-Bipand anti-HA detection. Lane 1-4: 
Protein equivalent to 2, 4, 8 and 16*105 cells, respectively. Bands for TbBipN were 
seen at approximately 55 kDa after anti-HA detection.  
    1     2    3     4   
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oligomannose, hybrid, and complex oligosaccharides and the asparagine residue from 
N-linked glycoproteins. During glycan removal, the modified asparagine residue is 
converted to aspartic acid. Hence, EndoH is only able to digest triantannary 
Man9GlcNAc2 that had been transferred by TbSTT3B, whereas PNGaseF can digest 
both Man9GlCNAc2 and biantennary Man5GlcNAc2 that had been transferred by 
TbSTT3A. Thus, a distinct digestion pattern, depending on what type(s) of glycan(s) are 
bound to the asparagine, can be visualised by Western blotting. The results after 
Western blotting are shown in Figure 3.3.3.  
 
 
 
 
It is evident that a molecular weight reduction due to glycan digestion, is only seen after 
treatment with PNGaseF. Since only PNGaseF was able to digest the glycan bound to 
Figure 3.3.3.Western blot results after anti-HA detection. Molecular weight 
reduction is only seen following PNGaseF treatment. Thus, the asparagine in the 
TEGLLNATDEIAL sequence had received an EndoH resistant biantennary 
Man5GlcNAc2 glycan from TbSTT3A. This result is in agreement with the 
hypothesis stating that sequons surrounded by acidic amino acids receive 
Man5GlcNAc2 from TbSTT3A (Izquierdo et al., 2009a). 
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the asparagine in the TEGLLNATDEIAL sequence, the glycan must be EndoH resistant 
and have originated from a biantennary Man5GlcNAc2, transferred by TbSTT3A (Figure 
3.3.3). Hence, the in vivo assay, using TbBipN as a glycosylation reporter protein, can 
distinguish between TbSTT3A and TbSTT3B transfer. 
 
 
3.3.3 Further validation of the in vivo N-linked glycosylation assay 
 
The in vivo assay indicated that it was possible to distinguish between TbSTT3A and 
TbSTT3B transfer,however, to be more confident that the assay was reliable, more 
positive controls were analysed using acceptor peptide sequences found in the T. brucei 
transferrin receptor. This protein is a dimer consisting of expression site associated gene 
6 and of expression site associated gene 7 (ESAG6 and ESAG7) and has a total of eight 
glycosylation sequons(Mehlert et al., 2012; Steverding et al., 1994). Four of these have 
previously been experimentally characterised and the other four were predicted 
according to the pI values of the acceptor peptidesequences (Mehlert et al., 2012). Two 
of the eight sequon-containing sequences (ERNALNATAANKV and 
LEEMRNASALAAA) were found on both ESAG6 and ESAG7, therefore only six 
sequences were analysed by the in vivo assay. To generate TbBipN constructs 
containing these acceptor peptides, forward and reverse DNA strands of the six 
sequences were synthesised individually in order to create duplex DNA with sticky ends 
upon annealing, as described in Figure 3.3.4. The annealed DNA sequences were 
subsequently cloned into the pLEW82 plasmid using the aforementioned AvrII and 
MfeI cloning sites.  
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The N-glycosylation of the six TbBipN fusion proteins was analysed as described in 
section 3.3.2 and the Western blot results are shown in Figure 3.3.5. 
 
Figure 3.3.4.Strategy for engineering new N-glycosylation reporter constructs. 
Forward and reverse DNA sequences were synthesised individually and 
subsequently annealed together to create sticky ends without any digestion steps. The 
annealed DNA sequence was then cloned into the pLEW82 plasmid using AvrII and 
MfeI restriction enzyme sites. 
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A B 
C D 
E F 
Figure 3.3.5. Western blot results after anti-HA detection. A: The glycans bound to 
the asparagine in the SPTRHNLTWGGGV sequence were sensitive to EndoH 
treatment, suggesting that Man
9
GlcNAc
2
 had been transferred by TbSTT3B. B: The 
glycans bound to the asparagine in the FGSYQNGSMYVEG sequence were both 
resistant and sensitive to EndoH treatment, suggesting that both Man
5
GlcNAc
2
 and 
Man
9
GlcNAc
2
 had been transferred by TbSTT3A and TbSTT3B.  
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When comparing the results in Figure 3.3.5 with the previous experimental and 
predicted results (Mehlert et al., 2012), a positive correlation was seen. The same OST 
enzyme (TbSTT3A or TbSTT3B) was shown to be utilizing these acceptor peptides, 
however, the Western blot results often indicated overlapping sequon preferences for 
TbSTT3A and TbSTT3B, displayed by the double bands. For example, the sequons in 
ERNALNATAANKV and LEEMRNASALAAA were previously predicted to receive 
Man9GlcNAc2 and Man5GlcNAc2, respectively, but the two TbBipN fusion proteins 
received both types of glycans. Although, the upper band in the ERNALNATAANKV 
Western blot was very weak, suggesting that most received oligosaccharides were the 
triantennary Man9GlcNAc2 transferred by TbSTT3B. A summary of the acceptor 
peptides investigated, their pI values and the experimentally (E) determined or predicted 
Figure 3.3.5.(continued) C: The glycans bound to the asparagine in the 
ERNALNATAANKV sequence were both resistant and sensitive to EndoH 
treatment, suggesting that both Man5GlcNAc2 and Man9GlcNAc2 had been 
transferred by TbSTT3A and TbSTT3B. However, Man9GlcNAc2 was the preferred 
glycan transferred to the sequon, since the lower band was much stronger. D: The 
glycans bound to the asparagine in the VCLNRNFTWGGGV sequence were 
sensitive to EndoH treatment, suggesting that Man
9
GlcNAc
2
 had been transferred by 
TbSTT3B. E: The glycans bound to the asparagine in the LEEMRNASALAAA 
sequence were both resistant and sensitive to EndoH treatment, suggesting that both 
Man5GlcNAc2 and Man9GlcNAc2 had been transferred by TbSTT3A and TbSTT3B. 
F:The glycans bound to the asparagine in the TILKSNYTAEPVR sequence were 
sensitive to EndoH treatment, suggesting that Man9GlcNAc2 had been transferred by 
TbSTT3B. 
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(P) utilization by TbSTT3A and TbSTT3B from the Mehlert et al. study compared to 
the result of the TbBipN in vivo study is seen in Table 3.3.1. 
 
Table 3.3.1.List of TfR sequons, their pI values, the experimentally determined (E) or 
predicted (P) utilization by TbSTT3A and/or TbSTT3Band the results of this study, 
experimentally determined using the in vivo assay (adapted from Mehlert et al., 2013). 
Site Sequon pI Transferring 
enzyme* 
Transferring 
enzyme** 
ESAG6/7 ERNALNATAANKV 8.9 TbSTT3B (E) TbSTT3A/B 
ESAG6 LEEMRNASALAAA 4.5 TbSTT3A (E) TbSTT3A/B 
ESAG7 LEEMRNASALAAA 4.5 TbSTT3A (P) TbSTT3A/B 
ESAG6 TILKSNYTAEPVR 8.3 TbSTT3B (E) TbSTT3B 
ESAG6 SPTRHNLTWGGGV 9.4 TbSTT3B (P) TbSTT3B 
ESAG6 FGSYQNGSMYVEG 4.0 TbSTT3A (P) TbSTT3A/B 
ESAG7 VCLNRNFTWGGGV 8.2 TbSTT3B (P) TbSTT3B 
*Mehlert et al., 2013 
**TbBipN in vivo assay (this study) 
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3.3.4 N-linked glycosylation of TbSTT3A and TbSTT3B 
 
With a robust in vivo assay, we wanted to investigate the sequon environments where 
the bound glycan type was unknown. Both TbSTT3A and TbSTT3B have N-X-S/T 
sequons, predicted to be found in loops on the protein surface (section 3.3.5), and are 
likely to be N-glycosylated. TbSTT3A has three sequons which are all shared with 
TbSTT3B, which has an additional fourth N-X-S/T site (Table 3.3.2).  
 
Table 3.3.2List of acceptor peptide sequences found in TbSTT3A and TbSTT3B. 
Protein Sequence pI 
TbSTT3A/B ITGIGNRTTLADG 6.2 
TbSTT3A/B IYKVMNVSEESKA 6.5 
TbSTT3A/B YLWLRNSTPEDAR 6.5 
TbSTT3B DFNRRNRSDAYYR 10.1 
 
One of the sequences (DFNRRNRSDAYYR) found in TbSTT3B has an isoelectric 
point value of 10.1, suggesting that an EndoH sensitive Man9GlcNAc2 will be 
transferredto the asparagine in the sequon. The other sequons (found in both TbSTT3A 
and TbSTT3B) had pI values close to neutral, giving no indication of preferred glycan 
transfer. Following electroporation, recovered cells were lysed as described above 
(section 3.3.2) and the lysate was diluted and incubated with either PNGaseF or EndoH. 
Samples were loaded on a SDS-PAGE gel and Western blotted using anti-HA antibody. 
The results are seen in Figure 3.3.6. 
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The asparagine within the DFNRRNRSDAYYR sequon peptide (TbSTT3B) was shown 
to receive an EndoH sensitive triantennary Man9GlcNAc2 from TbSTT3B, which was 
predicted from the relatively high pI value of 10.11 (Figure 3.39 A). A similar digestion 
pattern was seen for B and C in Figure 3.3.6, indicating that the asparagine within the 
A 
C 
B 
D 
Figure 3.3.6. Western blot results after anti-HA detection. A, B and C: The glycans 
bound to the asparagines in the DFNRRNRSDAYYR, ITGIGNRTTLADG and 
IYKVMNVSEESKA sequences were EndoH sensitive, suggesting that a 
triantennary Man
9
GlcNAc
2
 had been transferred by TbSTT3B. D: Changes in 
mobility following both EndoH and PNGaseF treatment indicated that there were 
two types of glycans bound to the asparagine in the YLWLRNSTPEDAR sequence, 
triantennary oligomannose oligosaccharides (EndoH sensitive) and biantennary 
oligosaccharides, hybrid and/or complex (EndoH resistant). 
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ITGIGNRTTLADG (pI 6.23) and IYKVMNVSEESKA(pI 6.52) sequon peptides, 
found in both TbSTT3A and TbSTT3B, had received an EndoH sensitive triantennary 
Man9GlcNAc2, transferred by TbSTT3B. The last peptide, YLWLRNSTPEDAR (pI 
6.51), is also found both in TbSTT3A and TbSTT3B and the digestion pattern was 
different compared to the results from the other sequon peptides. It was evident that the 
mobility changed following EndoH treatment, even though the top of the band was at 
similar molecular weight as the untreated sample.This indicates that both types of 
glycans were bound to the asparagine in the sequon(Figure 3.3.6 D). 
In summary, the results suggested that TbSTT3A is able to autoglycosylate one of its 
three sequons (also found in TbSTT3B), whereas TbSTT3B seems to be able to 
glycosylate all sequons found in the two oligosaccharyltransferase enzymes. The sequon 
suggested to be acted upon by TbSTT3A (YLWLRNSTPEDAR)has two acidic amino 
acids downstream of the sequon which might influence TbSTT3A transfer, supporting 
the hypothesis suggested by Izquierdo and colleagues (Izquierdo et al., 2009a). The 
DFNRRNRSDAYYR and ITGIGNRTTLADG peptides also have some acidic residues 
flanking the sequon, however, the arginine found between the asparagine and the 
serine/threorine in both peptides might have a negative effect on TbSTT3A catalysed 
transfer. Intriguingly, IYKVMNVSEESKA also has two acidic amino acids 
downstream of the sequon, similar to YLWLRNSTPEDAR, but seems to receive only 
an EndoH sensitive triantennary Man9GlcNAc2, transferred by TbSTT3B. The results 
also support the suggestion that TbSTT3B has a broader acceptor peptide tolerance 
around the glycosylation sequon.  
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3.3.5 Investigation of TbSTT3A and TbSTT3B acceptor peptide specificity 
 
It has been previously published (Izquierdo et al., 2009a) that TbSTT3A prefers to 
transfer Man5GlcNAc2 to sequons that are surrounded by acidic amino acids and the 
results from TbSTT3A and TbSTT3B glycosylation (3.3.4) supported this hypothesis. 
Furthermore, Izquierdo et al suggested that TbSTT3C also displayed a preference for 
acidic acceptor peptides (based on its expression in S.cerevisiae and subsequent analysis 
of the glycoproteome). To get a better understanding of why TbSTT3A and TbSTT3C 
seem to prefer acceptor peptides with acidic residues surrounding the sequon, the amino 
acid sequences of TbSTT3A, TbSTT3B and TbSTT3C were compared (Figure 
3.3.7).TbSTT3A and TbSTT3C have more positively charged amino acids 
thanTbSTT3B. The positions in the sequence alignment where both TbSTT3A and 
TbSTT3C have either a lysine or an arginine residue, but TbSTT3B does not, are 
highlighted with red boxes in Figure 3.3.7. At position 397, an arginine is found in 
TbSTTA and TbSTT3C, compared to the histidine found in TbSTT3B. Histidine is also 
a basic amino acid but the pKa value of 6.10 is considerably lower than the pKa value 
of arginine (12.48). Furthermore, the structure also differs between the bulkier 
imidazole ring of histidine and the long, side chain of arginine. In position 406 and 665, 
arginines are found in TbSTT3A and TbSTT3C, whereas a glycine is found in 
TbSTT3B. In position 558, the positively charged lysine and arginine are found in 
TbSTT3A and TbSTT3C, compared to a neutral glutamine residue found in TbSTT3B. 
Finally, position 567 is occupied by arginines in TbSTT3A and TbSTT3C, whereas a 
glutamine is found in TbSTT3B. These positively charged amino acids, specific for 
TbSTT3A and TbSTT3C, might play a role in explaining the preference of acidic 
acceptor peptide sequons seen for these two enzymes. 
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To this date, there are no structural data for the three oligosaccharyltransferase enzymes 
in T. brucei. Therefore, to be able to investigate if any of the positively charged residues 
specifically found in TbSTT3A and TbSTT3C are near the active site of the enzymes, 
models of the enzymes were built using Phyre2 (Kelley and Sternberg, 2009). Briefly, 
this program searches for homologues through a PSI-blast, then generates a hidden 
Markov model for a protein. At the same time it extracts the protein sequence for 
approximately 65.000 known structures and creates hidden Markov models for each of 
Figure 3.3.7.Protein sequence alignment of TbSTT3A, TbSTT3B and TbSTT3C. 
Positively charged amino acids found in TbSTT3A and TbSTT3C, not found in 
TbSTT3B, are highlighted in red boxes. Adapted from Izquierdo et al, 2009. 
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them, generating a database of these known models. Subsequently, the protein sequence 
is scanned through the abovementioned database to generate an alignment between the 
sequence being examined and the sequence of known structures. The top hit in this 
analysis was the crystal structure of C. lari OST (Lizak et al., 2011), followed by crystal 
structures of OST C-termini from various organisms. Although C. lari OST only share 
approximately 20 % of the protein sequence of TbSTT3A, TbSTT3B and TbSTT3C, 70 
% of STT3A and 67 % of TbSTT3B and TbSTT3C protein sequences were modelled 
with 100 % confidence. Figure 3.3.8 showns the crystal structure of the PglB enzyme 
found in C. lari (yellow, A) and the model structures of TbSTT3B and TbSTT3C (red, 
B and purple, C) (The PyMOL Molecular Graphics System, Version 1.5.0.4 
Schrödinger, LLC.).TbSTT3B and TbSTT3C have 95 % sequence identity (Izquierdo et 
al., 2009a)but still have different preferencesfor acceptor peptides. Therefore, these 
models are interesting to investigate, in trying to understand why TbSTT3C (and 
TbSTT3A) prefer sequons surrounded by acidic residues. The amino acids known to 
participate in catalysing the glycan transfer in C. lari are highlighted in magenta. These 
amino acids are conserved in TbSTT3B and TbSTT3C and were highlighted in cyan 
(TbSTT3B) and yellow (TbSTT3C). The acceptor peptide (GDQNAT) that was bound 
to the C. larioligosaccharyltransferase, is seen highlighted in orange (superimposed in 
T. brucei models). 
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A 
B 
Figure 3.3.8 
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C 
Figure 3.3.8.Crystal structure of C. lari and model structures of TbSTT3B and 
TbSTT3C.A: (Previous page) The C. lari oligosaccharyltransferase is seen in yellow, 
with amino acids proposed to be involved in glycan transfer highlighted in magenta. 
The bound acceptor peptide (GDQNAT) is seen in orange. B: (Previous page) The 
model of TbSTT3B is seen in red, with conserved amino acids that presumably are 
involved in glycan transfer highlighted in cyan. The superimposed acceptor peptide 
(GDQNAT) is seen in orange. C: The model of TbSTT3C is seen in purple, with 
conserved amino acids that presumably are involved in glycan transfer highlighted in 
yellow. The superimposed acceptor peptide (GDQNAT) is seen in orange. 
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Four out of the five amino acid positions from Figure 3.3.9 are seen in the TbSTT3 
models (residue 558 – K in TbSTT3A, Q in TbSTT3B and R in TbSTT3C – is not part 
of the models). All four of the observable amino acids are predicted to be positioned 
close to the active site and residue 397 (H in TbSTT3B and R in TbSTT3C) is 
positioned on the loop that has previously been reported to be involved in acceptor 
peptide binding in the C. lari oligosaccharyltransferase (Lizak et al., 2011). The four 
residues are seen in stick structure, highlighted in green. Furthermore, the superimposed 
acceptor peptide (GDQNAT) that was bound to the C. lari oligosaccharyltransferase, is 
seen highlighted in orange and the conserved amino acids previously reported to take 
part in catalysing glycan transfer(Lizak et al., 2011)are highlighted in cyan (TbSTT3B) 
and yellow (TbSTT3C).  
 
 
Figure 3.3.9.(Next page) Structural models of active sites of TbSTT3B (red) and 
TbSTT3C (purple). Amino acids that presumably are involved in glycan transfer 
highlighted in cyan (TbSTT3B) and yellow (TbSTT3C). The acceptor peptide 
(GDQNAT) that bound to the C. lari oligosaccharyltransferase is superimposed and 
highlighted in orange. The residues which are positively charged in TbSTT3C but 
not in TbSTT3B are highlighted in green. The arginine at position 397 in TbSTT3C 
seems to point straight towards the acceptor peptide in the active site. 
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The arginine at position 397 points straight at the acceptor peptide and could perhaps be 
involved in selection of acidic glycosequon sequences in TbSTT3A and TbSTT3C. 
Examining the differences in the amino acid sequences between TbSTT3B and 
TbSTT3C, suggests reasons why TbSTT3A and TbSTT3C prefer acceptor peptides with 
acidic residues surrounding the N-X-S/T sequon. Using the in vivo glycosylation assay 
it was possible to investigate how each position flanking the sequon affects TbSTT3A 
transfer. An aspartic acid scan was performed across the eleven Ala residues of the 
sequence shown in Table 3.3.3. All these peptides have the same pI value (3.10) and 
according to the current hypothesis they should all receive a biantennary Man5GlcNAc2 
from TbSTT3A. A sequence with only alanine surrounding the sequon, with a pI of 6.01 
and expected to receive Man9GlcNAc2 from TbSTT3B, was used as a negative control. 
 
Asn Asn 
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Table 3.3.3.List of sequences analysed by the in vivo glycosylation assay. 
Name Sequence pI 
Alanine control AAAAANATAAAAA 6.01 
D -5 DAAAANATAAAAA 3.10 
D -4 ADAAANATAAAAA 3.10 
D -3 AADAANATAAAAA 3.10 
D -2 AAADANATAAAAA 3.10 
D -1 AAAADNATAAAAA 3.10 
D +1 AAAAANDTAAAAA 3.10 
D +3 AAAAANATDAAAA 3.10 
D +4 AAAAANATADAAA 3.10 
D +5 AAAAANATAADAA 3.10 
D +6 AAAAANATAAADA 3.10 
D +7 AAAAANATAAAAD 3.10 
 
Following electroporation, recovered cells were lysed and the lysate was diluted and 
incubated with either PNGaseF or EndoH. Samples were loaded on a SDS-PAGE gel 
and Western blotted using anti-HA antibody. The SDS-PAGE gels were run over a 
longer time to separate potential double bands in order to facilitate band quantification 
using the Licor scanner software. The EndoH digestion indicates whether more than one 
glycan was transferred to the sequon by displaying two bands following Western 
blotting. If two bands are seen, the upper band indicates the TbBipN molecules that 
received EndoH resistant Man5GlcNAc2 from TbSTT3A. The lower band indicates 
TbBipN molecules which received EndoH sensitive Man9GlcNAc2 from TbSTT3B. 
Figure 3.3.10 shows the Western blot results after EndoH digestion of three of the 
transfected TbBipN constructs.  
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There are double bands seen in all lanes in Figure 3.3.10, suggesting that both 
TbSTT3A and TbSTT3B transferred glycans to the sequons. However, the upper band 
of the AAAAANATAAAAA control sequence is weaker that in the other lanes, 
suggesting that TbSTT3A contributed less in glycan transfer. These bands could be 
quantified using the Licor scanner system software to calculate TbSTT3A transfer to 
each sequon-containing secuence. Three biological replicates, starting from the same 
cell density, were analysed three times each. PNGaseF and EndoH were added in excess 
to assure digestion going to completion. The collective results from all the analyses are 
seen in Figure 3.3.11. 
 
Figure 3.3.10.Western blot results after EndoH digestion. Double bands were seen in 
all lanes, suggesting that both TbSTT3A and TbSTT3B have transferred glycans to 
the sequons. The less intense band seen for the AAAAANATAAAAA sequence 
implies that TbSTT3A did not contribute much in the glycan transfer to the neutrally 
charged control sequence, in agreement with the current hypothesis . 
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The neutral control sequence, only containing alanines, showed about 5 % TbSTT3A 
transfer. This was expected since no acidic amino acids are found in the flanking 
positions of the sequon. Introducing a single aspartic acid into the sequon peptide in 
various positions reduces the pI uniformly and should allow more TbSTT3A transfer. 
However, although the overall pI of the region was uniformly reduced in all sequon 
Figure 3.3.11. Graph visualising how TbSTT3A glycan transfer is affected by one 
single aspartic acid in and around the sequon. The negative control sequence (Ala) 
received approximately 5 % of its glycans from TbSTT3A. A single aspartic acid in 
any of the -5 to -2 upstream positions of the sequon generated approximately 35 % 
TbSTT3A transfer. A single aspartic acid in any of the +3 to +7 downstream 
positions influenced TbSTT3A transfer to between 10-25 %. The most striking 
effect, however, was seen when a single aspartic acid was introduced immediately 
adjacent to the asparagine of the sequon, which switched the TbSTT3A glycan 
transfer to 60-70 %.  
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peptides, acidity in certain positions had a bigger impact on TbSTT3A transfer. An 
aspartic acid in the upstream positions -5, -4, -3 and -2 generates about 35 % TbSTT3A 
transfer, whereas the downstream positions 3,4,5,6 and 7 only ranges between 10-25 %. 
The most influential positions for TbSTT3A transfer were the sites immediately 
adjacent to the asparagine. A single aspartic acid in these positions switched TbSTT3A 
transfer to about 60-70 % compared to the 5% transfer when no aspartic acid was 
introduced. These results made us reassess the current hypothesis of acceptor peptide 
specificity.  
This new hypothesis was supported by analysing sequon-containing sequences where 
the type(s) of glycan(s) attached to the asparagine where known. The data set 
(Rodriguez, Izquierdo, Procter and Ferguson, unpublished) was previously gathered 
following proteomic analysis subsequent to EndoH and PNGaseF digestion. Briefly, 
glycoproteins were captured from VSG‐depleted cells followed by digestion with 
EndoH and subsequently by PNGaseF. Hence, EndoH‐sensitive glycopeptides appear 
203 Da heavier by mass spectrometry due to the GlcNAc residue left attached to the 
asparagine residues by endoH whereas the remaining endoH‐resistant, but 
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PNGaseF‐sensitive, sites appear 1 Da heavier because of the conversion of the 
asparagine residues to Asp by PNGaseF. The acceptor peptides that were shown to only 
receive a biantennary Man5GlcNAc2 from TbSTT3A (appendix) were used to create a 
motif logo (Figure 3.3.12). More acidic (red) than basic (blue) amino acids are found in 
these acceptor peptides, as expected. Also, more glutamic acids than aspartic acids were 
present, however, no other clear pattern was seen. Conversely, when looking closer at 
the sequon-containing sequences that had TbSTT3B transferred triantennary 
Man9GlcNAc2 bound to the asparagine, a pattern could be seen (Figure 3.3.13). Firstly, 
more basic (blue) than acidic (red) amino acids were found in the acceptor peptides, 
which was expected. Some acidic amino acids were seen, but they were mostly found 
downstream of the sequon. No acidic residues were seen in position -4, -3, -2 and +1 
and only one acidic residue was seen in position -5 and -1. This is interesting as 
TbSTT3B acts upon the protein after co-translational glycosylation by TbSTT3A. 
Therefore, it seems like the acceptor peptides that contain a negatively charged amino 
acid in any of these positions are (mostly) acted upon by TbSTT3A, which is in 
agreement with the results seen in Figure 3.3.11. 
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Figure 3.3.12.Motif logo of 90 acceptor peptides that had exclusively received 
biantennary Man5GlcNAc2 from TbSTT3A. The numbers of acidic (red box) and 
basic (blue box) amino acids in different positions of the acceptor peptides are 
highlighted. More negatively charged amino acids where found in and around the 
sequon compared to positively charged. Furthermore, more glutamic acids than 
aspartic acids were seen except in position +6. 
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Figure 3.3.13.Motif logo of 29 acceptor peptides that had exclusively received 
triantennary Man
9
GlcNAc
2
 from TbSTT3B. The numbers of acidic (red box) and 
basic (blue box) amino acids in different positions of the acceptor peptides are 
highlighted. More positively charged amino acids (blue) where found in and around 
the sequon compared to negatively charged residues (red). Furthermore, no acidic 
residues were seen in position -4, -3, -2 and +1 and only one negatively charged 
residue was seen in position -5 and -1. This suggests that peptides with acidic 
residues in these upstream positions had already been acted upon by TbSTT3A. 
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The results seem to suggest that acidity in the upstream positions (-5, -4, -3, -2) of a 
glycosylation sequon are more important for selective TbSTT3A glycan transfer than 
the downstreams positions (+3, +4, +5, +6, +7). Interestingly, according to the results in 
Figure 3.3.11, a single aspartic acid in any of the immediately adjacent positions (-1 or 
+1) significantly improvesTbSTT3A glycan transfer. Just like TbSTT3C (Figure 3.42), 
TbSTT3A also has an arginine at position 397 which seems to point straight into the 
active site where the acceptor peptide binds (Figure 3.3.14) This arginine is predicted to 
be found in a loop which has previously been reported to be a part of acceptor peptide 
binding in C. lari (Lizak et al., 2011, 2014).In Figure 3.3.14, the active site of TbSTT3A 
with a superimposed acceptor peptide (GDQNAT) is seen. The asparagine of the 
sequon is highlighted in black, the two immediately adjacent positions (-1 and +1) in 
beige and the rest of the acceptor peptide in orange. The arginine in position 397 is 
highlighted in magenta. 
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Taken together, these data give a greater insight of TbSTT3A and TbSTT3B acceptor 
sequence specificity in T. brucei. Although the overall pI gives a good indication of 
selective recognition by TbSTT3A, we have shown that upstream amino acids and 
particularly amino acids immediately adjacent to the asparagine play a crucial role in 
TbSTT3A and TbSTT3B acceptor peptide specificity. Whether the effects seen in 
TbSTT3A 
Figure 3.3.14 Structural model of active site of TbSTT3A. An acceptor peptide 
(GDQNAT) is superimposed and the asparagine of the glycosylation sequon is 
shown in black. The two immediately adjacent positions (-1 and +1) are beige and 
the rest of the peptide is orange. The asparagine in position 397 (magenta) seems to 
point at the acceptor peptide and may be involved in recognition and binding. This 
positively charged amino acid is found in a loop which has previously been reported 
to contribute to acceptor peptide binding in C. lari(Lizak et al., 2011, 2014). 
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Figure 3.3.11 are additive or whether the effect of the most significant acidic amino 
acids is dominant remains to be determined. Similarly, we need to assess whether 
glutamate has a similar, greater or lesser effect than aspartate. Furthermore, it is 
interesting that the arginine in position 397 in the TbSTT3A and TbSTT3C models is 
predicted to point towards the acceptor peptide, seemingly being close to the two 
immediately neighbouring residues of the asparagine. Additionally, the arginine is, 
according to the model, positioned in a loop that has previously been shown to facilitate 
binding of acceptor peptides in C. lari(Lizak et al., 2011, 2014). Whether this positively 
charged amino acid plays a role in recognising and binding acidic residues upstream 
and/or immediately adjacent the asparagine, remains to be determined. 
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4 – Discussion 
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4.1 Essentiality of TbSTTA - generation of TbSTT3A gene replacement mutants 
 
In two separate attempts to create a TbSTT3 conditional null mutant, the data from the 
PCR screens and the Southern blot experiments (Figure 3.1.11, 3.1.13, 3.1.14 and 
3.1.16) showed that BSD had successfully replaced the last endogenous TbSTT3A 
copy, but that new (weak) TbSTT3-probe hybridising bands, which were clone specific, 
were seen in the gene replacement cells. Furthermore, the glycosylation pattern of sVSG 
following gene replacement (Figure 3.1.18), showed that the TbSTT3A function was 
retained under non-permissive conditions. These results might suggest that the cells 
have rearranged their genome during TbSTT3A replacement, which would imply that 
the tetracycline-inducible ectopic copy could not complement for the loss of the 
endogenous TbSTT3A gene, suggesting that it is essential for cell viability in vitro. 
Interestingly, a recent study has reported that gene rearrangement had occurred in the 
TbSTT3 locus when cells were exposed to lethal concentrations of the mannose specific 
Hippeastrum Hybrid Agglutinin (HHA) (Castillo-Acosta et al., 2013). HHA 
preferentially binds to oligomannose glycans that originate from TbSTT3B transfer of 
Man9GlcNAc2 and, after establishing a resistant cell line, it was shown that the 
endogenous TbSTT3B was replaced by two novel chimeric genes, TbSTT3B/C/B and 
TbSTT3C/B/C. It was postulated that the cells had rearranged the TbSTT3 locus in 
order to express TbSTT3 proteins that do not transfer Man9GlcNAc2 efficiently, thus 
reducing the endocytosis of HHA and keeping the cells alive (Castillo-Acosta et al., 
2013).  
In order to test if something similar occurred during TbSTT3A replacement, it should be 
possible to extract gDNA from the gene replacement cells and sequence the TbSTT3 
locus. Additionally, to elucidate why the ectopic copy of was not able to complement 
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gene replacement of the last endogenous copy of TbSTT3A, it would be interesting to 
sequence the ectopic copy of TbSTT3A incorporated into the ribosomal RNA spacer 
locus to check for errors or mutations. For future gene replacement trials, it would be 
beneficial to use a C-terminally tagged ectopic copy of TbSTT3A, which enables 
detection by Western blotting to verify that the gene is induced correctly following 
addition of tetracycline. The pLEW100v5 plasmid is similar to the original pLEW100, 
but a few useful differences could make that plasmid a better choice for introduction of 
the ectopic TbSTT3A copy. The rRNA promoter gives pLEW100v5 a higher expression 
level which could be important during future TbSTT3A gene replacement trials.  
An alternative strategy to test the essentiality of TbSTT3A and TbSTT3B in vitro might 
be the removal of the whole last TbSTT3 locus from the 
[TbSTT3A/TbSTT3B/TbSTT3C]+/- heterozygote cell line after introduction of different 
ectopic copies. In this approach, we would predict that ectopic expression of TbSTT3A 
and TbSTT3B using pLEW100v5 should allow us to successfully replace the whole of 
the remaining endogenous TbSTT3 locus, in a similar way to that used to generate the 
heterozygote (Izquierdo et al., 2009a). However, if either TbSTT3A and/or TbSTT3B 
is/are essential for growth in vitro, then we will be unable to replace the remaining 
endogenous TbSTT3 locus (Figure 4.1). 
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Figure 4.1.Alternative strategy to investigate TbSTT3A and TbSTT3B essentiality in 
vitro. Introduction of pLEW100v5 carrying a tetracycline-inducible ectopic copy of 
TbSTT3A and TbSTT3B (A), TbSTT3A (B) or TbSTT3B (C) followed by 
replacement of the last STT3 allele with HYG. Over expressing both TbSTT3A and 
TbSTT3B simultaneously should rescue allele replacement, while individual 
introduction of either would not support cell growth if the TbSTT3A and TbSTT3B 
genes are essential.  
A 
B 
C 
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4.2 The search for novel TbSTT3A binding partners 
 
Even though the T. brucei genome does not encode for any identifiable OST subunit 
homologues other than the three TbSTT3 genes(Berriman, 2005), we decided to 
investigate whether there were any novel OST subunits bound to TbSTT3A. This was 
important to do experimentally given the evolutionary distance of the kinetoplastids 
from other eukaryotic lineages. For example, previous studies in T. bruceihave shown 
that novel clathrin-associating proteins were found and similarly, two novel subunits of 
the GPI transamidase werefound in T. brucei and shown to only have homologues in 
Leishmania and Trypanosoma cruzi(Adung’a et al., 2013; Nagamune et al., 2003).We 
therefore used in situ tagged TbSTT3A as bait to search for novel TbOST subunits by 
blue native gel electrophoresis and immunoprecipitation experiments.  
Before initiating immunoprecipitation under mild solubilisation conditions, optimisation 
of the percentage of digitonin was performed in order to minimise the risk of losing 
weakly associated partners, while still ensuring sufficient solubilisation of the 
membrane-bound TbSTT3A. A literature search suggested that 1 % digitonin was a 
common choice for both co-immunoprecipitation in T. brucei and for pulldowns of 
bigger complexes (for example OST) in other organisms (Oeljeklaus et al., 2012; 
Roboti and High, 2012a; Singha et al., 2012). However, it is clear in Figure 3.2.8, that, 
for example, the VSG dimer falls apart into the monomeric state when using 1 % 
digitonin. Further, since TbSTT3A solubilisation appeared to be efficient at 0.5 % 
digitonin we elected to use this detergent concentration in our further 
immunoprecipitation and blue native gels electrophoresis experiments. 
The TbSTT3A-HA3immunoprecipitationof SILAC labelled components gave relatively 
clear results concerning potential novel OST subunits in T. brucei. Both TbSTT3A 
(bait) and TbSTT3B were highly enriched in the pull-down and only three other proteins 
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had significantly enriched heavy to light isotope ratios (i.e., above the 3 sigma cut-off). 
However, these three proteins were 7-fold less enriched than TbSTT3B and are not 
known to localise in the ER, suggesting that TbSTT3B was the only protein specifically 
bound to TbSTT3A during the immunoprecipitation experiment. It is worth noticing 
that although TbSTT3A and potential associated proteins are expected to be specifically 
enriched, 500 other proteins were detected by mass spectrometry in the pull-down. 
Performing immunoprecipitation under SILAC methodology greatly simplifies 
recognition of true interacting proteins and can be used as a powerful tool for 
deconvoluting the complex datasets that typically emerge from pull-down experiments. 
The association between these two STT3 isoforms was further strengthened by the co-
immunoprecipitation results (Figure 3.2.16). Taking these findings together with the 
large TbSTT3A-containing complex observed after blue native gel electrophoresis, we 
propose that TbSTT3A and TbSTT3B form a heteromeric OST complex in T. brucei. 
The reciprocal immunoprecipitation of TbSTT3B under SILAC conditions will be 
performed to validate the interactions between TbSTT3A and TbSTT3B and to confirm 
that no other potential OST subunit proteins are associated with T. brucei OSTs. 
Additionally, it would be tempting to use the TbSTT3A-HA3–TbSTT3B-MYC3 cell line 
to repeat the blue native gel experiment, enabling simultaneous detection of the two 
proteins in the high molecular weight complex. 
Similar to T. brucei, the Leishmania major genome only encodes for the OST catalytic 
subunit STT3. Of the four STT3 genes in Leishmania major, three (TmSTT3A, 
LmSTT3B and LmSTT3D) were able to rescue STT3 deficiency in yeast cells. Further, 
the LmSTT3 proteins were not incorporated into the yeast OST complex (Nasab et al., 
2008). Interestingly, these single subunit OSTs were suggested to form homodimers in 
their yeast host andLmSTT3A was even detected between approximately 500 and 700 
kDa by Western blotting following blue native gel electrophoresis. However another 
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study proposed that LmSTT3A, LmSTT3B and LmSTT3D possessed anomalous 
migration behaviour and that they were functional as a monomeric OST in yeast (Hese 
et al., 2009). Despite these contradicting suggestions, it is interesting to question 
whether L. major STT3s can form homodimers, heterodimers or (as we speculate in T. 
brucei) multimeric OST complexes. Multiple copies of STT3 genes have also been 
reported in bacterial and archaeal genomes, opening up the possibility of more 
multimeric STT3 OST complex discoveries (Jervis et al., 2010; Magidovich and 
Eichler, 2009).  
While higher eukaryotes have evolved increased complexity of OST subunit 
composition, which may reflect a diversity of protein substrates and sequons, T. 
bruceiOST seems to consist solely ofTbSTT3A and TbSTT3B, bound together, in 
bloodstream form parasites. Since the glycosylation efficiency has been suggested to be 
rather high in the parasite cells(Izquierdo et al., 2009a), it is interesting to question 
whetherT. brucei OST has the glycosylation “fine tuning” capabilities described for the 
OSTs of higher eukaryotes. For example, the mammalian OST subunits MagT1/IAP 
and TUSC3/N33, and their Ost3 and Ost6 homologues in yeast, share lumenal 
thioredoxin domains(Cherepanova et al., 2014; Fetrow et al., 2001; Kelleher and 
Gilmore, 2006; Mohorko et al., 2014). It has been suggested that MagT1/IAP and 
TUSC3/N33 can form transient mixed disulfides with a free thiols in nascent 
glycoproteins, hence delaying disulfide bond formation and giving more time for 
glycosylation to occur. Furthermore, MagT1/IAP has been proposed to react with a 
disulfide in a nascent glycoprotein when in its reduced form, thus allowing access of 
STT3B to previously inaccessible sequons (Cherepanova et al., 2014). T. brucei STT3s 
do not have the CxxC motif found in MagT1/IAP and TUSC3/N33 and the Ost3 and 
Ost6, but a CxC site is present in TbSTT3B and TbSTT3C and this motif has been 
reported to have disulfide isomerase activity(Woycechowsky and Raines, 2003). 
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Interestingly, TbSTT3B has been shown to have a broader acceptor peptide preference 
than TbSTT3A (Izquierdo et al., 2009a) and perhaps this cysteine motif could add 
oxidoreductase features that expand the range of acceptable sequon environments 
forglycosylation byTbSTT3B. The CxC motif of TbSTT3B is predicted to be in the EL5 
loop that has been shown to interact with the acceptor polypeptide (Lizak et al., 2011, 
2014). Perhaps the cysteines in the CxC motif can form transient mixed disulphides 
with the nascent protein in order to enhance the efficiency of TbSTT3B glycosylation. 
It would be possible to investigate the influence of cysteine residues adjacent to 
glycosylation sequons using the TbBipN in vivo assay system described in this thesis. 
Thus, we could investigate whether the presence of adjacent Cys residues might reduce 
their recognition by TbSTT3A and increase their utilisation by TbSTT3B.  
 
4.3 Acceptor peptide substrate specificity of TbSTT3A and TbSTT3B 
 
The result of a single aspartic acid introduced into variable flanking positions clearly 
showed that a low pI value alone for acceptor peptides is not sufficient to explain the 
differences between TbSTT3A and TbSTT3B sequon specificity. Although the overall 
pI of the acceptor peptide was uniformly reduced by aspartic acid in all sequon peptides, 
acidity in certain positions had a bigger impact on TbSTT3A transfer and these results 
made us reassess the current hypothesis of acceptor peptide specificity. We showed that 
upstream amino acids and particularly amino acids immediately adjacent to the 
asparagine, play a dominant role in TbSTT3A and TbSTT3B acceptor peptide 
specificity. The TbSTT3B-utilised glycosylation site motif logo supported this view 
and, together with the molecular model data for theT. brucei STT3s, it is tempting to 
suggest a possible role for the arginine residue in position 397 (R397), found in 
TbSTT3A and TbSTT3C but not in TbSTT3B, playing a role in acceptor site 
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recognition by TbSTT3A and TbSTT3C. Since R397 is predicted to be in the C-terminal 
part of the flexible EL5 loop, which has been proposed to be involved in acceptor 
peptide binding(Lizak et al., 2011, 2014), it is possible that the basic arginine side-chain 
can ‘scan’ the sequon flanking residues and interact electrostaticallywith acidic amino 
acids and thereby enhance the recognition of specific sequons. It is important to be 
careful when making assumptions based on molecular models, however, more evidence 
about the involvement of R397 in T. brucei STT3 sequon specificity was published 
recently (Castillo-Acosta et al., 2013). The chimeric TbSTT3B/C/B protein described in 
this paper showed much less efficient recognition of the asparagine 428 (N428) 
glycosylation site in VSG221, normally the native choice of TbSTT3B. In other words, 
the TbSTT3B/C/B chimeric OST appeared to have attained a peptide acceptor 
specificity more similar to TbSTT3A than TbSTT3B. Within the C component of the 
TbSTT3B/C/B chimeric protein, there are only 11 amino acids changes. Interestingly, 
one of these is H397R. This supports the notion that the presence of R397 in TbSTT3A 
(and the TbSTT3B/C/B chimera) is the reason why these OSTs skip the N428 
glycosylation site of VSG221 thathas no acidic residues near the sequon 
(KTGNTNTTGSSNS). Based on these observations, we have engineered point 
mutations at position 397 in TbSTT3B and TbSTT3C (initially H397R in TbSTT3B and 
R397H, R397D, R397Q in TbSTT3C) and these, together with wild type TbSTT3B and 
TbSTT3C, will be used to complement yeast OST mutants and analyse glycosylation 
site utilisation in yeast using an MS based method in Professor Markus Aebi’s lab at 
ETH in Zurich. According to our current thinking, the H397R mutation in TbSTT3B 
should make this OST more like TbSTT3A and TbSTT3C with respect to acceptor 
peptide specificity, whereas R397H, R397D, R397Q in TbSTT3C might be expected to 
make this OST more like TbSTT3B with respect to acceptor peptide specificity. 
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Lastly, since charge seems to play an important role in TbSTT3 sequon specificity, it is 
noticeable that three of the other amino acids that changed in the TbSTT3B/C/B chimer 
were D402G, D403A and G406R. All these amino acid changes could be argued to 
reduce the ability of the enzyme to recognise the VSG221 N428 glycosylation site 
(KTGNTNTTGSSNS), when looking at their predicted locations in TbSTT3B (Figure 
4.2).  
 
 
 
Figure 4.2.Model of the TbSTT3B active site. The superimposed acceptor peptide 
(GDQNAT)is seen binding conserved residues that where involved in catalysing 
oligosaccharide transfer in C. lari (cyan) and the four residues involved in charge 
change in TbSTT3B/C/B are highlighted in green (changed into basic arginines) and 
blue (acidic residues changed into neutral). 
142 
 
In this model, the residues 397, 402, 403 and 406 line up just below the glycine in the 
superimposed acceptor peptide (GDQNAT) and it is possible that a longer acceptor 
peptide could interact with these residues. Therefore, it is appealing to suggest that the 
lysine in the -5 position in the N428 acceptor peptide might interact with one of the two 
aspartic acids in TbSTT3B and that this interaction is lost in the TbSTT3B/C/B chimera, 
thus reducing recognition of the sequon. It is also interesting to note that the N263 
sequon of VSG221, which is acted upon exclusively by TbSTT3A, has a glutamic acid 
immediately adjacent to the asparagine (TAEFRNETAGIAG), in agreement with the 
results showing that acidity in position -1 and +1 heavily influence TbSTT3A transfer of 
Man5GlcNAc2. 
It might be possible to investigate how some of the residue changes seen in the 
TbSTT3B/C/B chimera (for example H397R, D402G and D403A) influence TbSTT3A 
and TbSTT3B glycosylation in vivo by using the protocol for in situ tagging TbSTT3A 
and TbSTT3B (Figure 4.3). In this way, different point mutations could be introduced 
into TbSTT3A and TbSTT3B that might switch the acceptor peptide specificities of the 
two proteins, such that TbSTT3A transfers Man5GlcNAc2 to a broad range of sequons 
while TbSTT3B transfers Man9GlcNAc2 to a reduced number of sequons, most likely 
those surrounded by acidic residues. This could subsequently be further tested by 
introducing the previously investigated (single aspartic acid) TbBipN acceptor peptides 
to probe specificity in a systematic way.  
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Figure 4.3. Strategy for mutation of the endogenous TbSTT3A and TbSTT3B using 
the in situ tagging protocol. Since a long stretch of the ORFs is used when in situ 
tagging, different mutations can be included in the tagging construct which will be 
transferred to the last allele of the endogenous genes via homologues recombination. 
The red star marks the point mutations. 
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5.1 pMOTag4M* construct for in situ tagging TbSTT3B 
 
gctgggtaccgggccGCAGATTGTTTCGCCGCTTCCGGAACAGAGCACGCCGACAG
TAAGGAGCATCAAGGGAAAGCCCGTGGTAAGGGACAGAAGGAACAAATCA
CTGTCGAGTGTGGGTGCCATAATCCCTTCTACAAATTATGGTGCAATTCATT
TTCCTCCCGCCTGGTAGTTGGTAAGTTTTTTGTCGTTGTTGTCCTTGCCATCT
GTGGACCCACATTTCTTGGGTCTAACCTCCGGATATATTCTGAGCAATTCGC
AGACAGCATGTCGAGCCCCCAGATTATAATGAGGGCAACTGTCGGTGGACG
ACGAGTTATCTTGGATGATTACTACGTGTCGTACTTGTGGCTGCGAAACAAT
ACGCCTGAAGATGCCCGTATTCTCTCATGGTGGGACTACGGGTATCAAATCA
CTGGAATTGGCAATCGCACAACCCTTGCGGATGGTAACACATGGAATCACG
AGCACATAGCAACTATTGGAAAGATGCTTACATCCCCTGTGAAGGAGTCAC
ATGCTCTTATACGCCATCTCGCTGATTATGTGCTGATATGGGCCGGTTATGA
TGGCAGCGATTTACTTAAATCGCCACACATGGCTCGGATAGGCAACAGTGT
ATATCGCGATATATGCTCAGAGGATGATCCGCTGTGTACGCAGTTCGGGTTT
TATAGTGGTGACTTCAGTAAACCTACGCCTATGATGCAGCGGTCCCTATTAT
ACAATCTGCACAGGTTTGGTACGGATGGCGGGAAGACACAACTGGATAAGA
ACATGTTTCAGCTCGCCTACGTGTCAAAGTATGGTTTGGTGAAGATCTACAA
GGTGATGAATGTGAGTGAAGAGAGCAAGGCGTGGGTTGCAGACCCAAAGA
ACCGCGTATGCGACCCACCCGGATCTTGGATATGCGCCGGCCAGTACCCGC
CAGCGAAGGAGATCCAAGACATGTTAGCGAAGAGGATTGACTACGAACAA
CTCGAGGATTTCAATCGCCGCAATCGAAGTGACGCTTATTATCGTGCGTATA
TGCGTCAGATGGGTCTGCAGGCGGGCGGCCGATCGAGATCCGAGGAGCAGA
AGCTGATCTCGGAGGAGGATCTGCTGAGATCCGAGGAGCAGAAGCTGATCT
CGGAGGAGGATCTGCTGAGATCCGAGGAGCAGAAGCTGATCTCGGAGGAG
146 
 
GATCTGCTGTGATCTAGTGCGGCCGTCGACAAAGTGTGACAACGTCGCACC
ATGTGTAGGTTTTCATTTATGTTCTTTCTTTCTTTCTTTTGTGAATTTGTTTTC
TGTCTCAAATGTTTTTAATTCGCTTGGGACCTATGTTTTTCTTGTTTTTTTGCT
CACCCTTTGTGTAGGAGGCACCCTGTCACGTCTGTGGTTGCGTGTATGCCTT
CCTTCCCCTTATTCGCTTCTTCCTGTCGTGTCACACCTCTTTCTCCCTCTCCCT
TTCCGCCTTTTCTTTCAATCTTGTTTTCTCGACCAGCCCTACTAGAGGAGAAA
GAATAGTAACCCTTTCATCAAAGAAAATAGTTCAAACGAATTGCTAGCTTA
AGCTTGATCTAGAACTAGTGATGGCCAAGCCTTTGTCTCAAGAAGAATCCA
CCCTCATTGAAAGAGCAACGGCTACAATCAACAGCATCCCCATCTCTGAAG
ACTACAGCGTCGCCAGCGCAGCTCTCTCTAGCGACGGCCGCATCTTCACTGG
TGTCAATGTATATCATTTTACTGGGGGACCTTGTGCAGAACTCGTGGTGCTG
GGCACTGCTGCTGCTGCGGCAGCTGGCAACCTGACTTGTATCGTCGCGATCG
GAAATGAGAACAGGGGCATCTTGAGCCCCTGCGGACGGTGCCGACAGGTGC
TTCTCGATCTGCATCCTGGGATCAAAGCCATAGTGAAGGACAGTGATGGAC
AGCCGACGGCAGTTGGGATTCGTGAATTGCTGCCCTCTGGTTATGTGTGGGA
GGGCTGACCCTGTGAAGATAAATTCGATTTGATGTGACAATGAAATAAGGT
ATGGGAAAGGGAGAACAAACTGATAAATGATAAGTGAATGAAGTAAAGTA
AGGAAGGCTGCCACTATATGCTTTGAGATTTTCATTTAACTATGTTATGCTG
TTGTTAGGGGTTAGAATCTTTTTTCTTGGTTTCCAATTAGGTATGCATTTCTT
TGTATTGGAGAATGTGAGGTTATCTTTTGGGGAGTGACAGCGTTTGGTACAT
TTATTAGGCGATCTATGGTGACATCGCCGCTTGTGCTCCCGTAAGTGCGTTA
GGTGGAGGTGTGCAGGTGTATCAACCTTGAAGGTTGTTCTCGCGCTGCGTTT
TCCATATATAGTAGTTAACTGTGATGCTGCGCATGACTAATTTTTCTGTTTAG
TCACTACACAGTCAGTTAACCTTTTTCCTTTCTGCCACTGTGTCGGGCGCAG
GTTGGTGTTCCACTGGTAACACTCCGTCATAACCAGGCGTGCACGTACCCTC
ACTCCCTGAAATGTGTGACACCGTGGTAAGGCCAACAATATGTCTTATTGAA
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ATACTTTCTGGTAATGATGTTGTTGAATATATGTATTGTTTGTCCCCAACCGT
GTTTGTGAATGCTTCATCTCGCTTGTATGCACTCGACTCTCCTCTTTCCACCA
CTCTCCCTAATTTGCTCAACAGTTAAGTCTGTTGTTCATAAAAAACTACGAG
GAAAATACGGAACCGGAGGGGCTCGTGACCGGTGTTGCTCGCTGAGGGAAC
CGTGTGTGAGCGAAGTCTAATATAATATCCGATTCGTCCTTTGGGCGTTTCT
TTCTGCTTATggaggtggatccggaggcggt 
 
Red: End of TbSTT3B 
Blue: MYC3 tag 
Yellow: Intergenic region 
Green: BSD 
Purple: 3’ UTR 
 
5.2 Acceptor peptide and HA3 tag for fusion with TbBipN glycosylation reporter 
protein 
 
ataagtaaCCTAGGGCGGCGGCGACCGAAGGCCTGCTGAACGCGACCGATGAAA
TTGCGCTGCAATTGGCGGCGGCGGAACAGAAACTGATTAGCGAAGAAGATC
TGGAACAGAAACTGATTAGCGAAGAAGATCTGGAACAGAAACTGATTAGC
GAAGAAGATCTGTTAATTAAttacttat 
 
Red: Restriction enzyme sites (AvrII, MfeI and PacI) 
Green: Ala3 linkers 
Blue: Acceptor peptide positive control (TEGLLNATDEIAL) 
Yellow: HA3 tag 
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5.3 Acceptor peptides exclusively acted upon by TbSTT3A 
 
TbSTT3A acceptor peptides 
TAEFRNETAGIAG SRLEGNDTDCPEE TILKSNYTAEPVR PVVVDNRSQAEER 
MKASINNTFEGPE GAAGENSSSPCTV CTLERNLTVAEML ELMTRNLSEQESA 
MTSVLNTTGYWAS EIILPNNTEEEEE EGVKGNLSGADVG QESAENSTQEKKS 
NTWETNYTVFVQQ EISCTNVTLDEKE DVGANQTEEEKD ILAANNYTVNQTD 
QTRFDNTTEEKLR LQEEKNHSEIISE KAAAANASAALDE NDKAGNHSAGEDD 
SDVAENVTAVKLL LEDGVNNTDLQDL TEGLLNATDEIAL VNAFENTTEGGHH 
QLSAANLTDFAHN TKENFNETIAKSE VHGNDNVTDQKKG AETSHNTTLIIEA 
PDPPFNFSAVVPE WEKAANETIDNAL QVAVRNDTLDFHA QSARDNATAAAVA 
DEMLNNRTDEVVE PELAANFSIRGYP DVGALNDTAVLSE ARLQANHTDCVYT 
KALGTNDSYVDPD GLTANNSTSLST KAAAANASAALDE VEIELNGTGLDAT 
DTWETNFTVFVQQ AMVKPNETASIEL LALFNNETQAVLT GEVSLNSTFRGRG 
VSDETNSSGLYRI KSNESNDSNESNV RELISNGSDALDK AQSYGNESETKTC 
PSTPTNSTKNEDS DKNTLNLTEYFKE NDLPLNVSREVLQ IGDEGNETKRTAL 
RGIATNETQVEVG FLHELNSTSSATK MKEQGNVSEEVNAE VARNENKTLEQAM 
VKRRRNNSQDVDT DAAVQNKSELPIV ERDVSNSTVVIAM KKAEDNVTHLKDY 
PATPTNSTKNEDS VELTDNNSAKCWI PVYRLNESVCYLK CEEAENETRDDLR 
EKMFRNETEFEKF KIGVVNGSDMENI EEVYANASRIIDN TDVYNNESDGGKY 
VVTPENISTEIVA RQLIGNITVPEQS LFAEVNESVRAVR NYEELNVSLSTLE 
EEIEENETTGKSE FMDDPNITEGRME DEVLENKSTSCLL WFKNFNYTISGLL 
VARNENKTLEEAM RFAPTNASTTAHT FLEKQNASDEDIV VESGANSTRGPSS 
SVDHANMSCGSYG LVRLDNASDPKQV KPESVNESVNTIL QRQPANATGEVAP 
MCDPENVTYGHTE EGILENTTALEPY NDVIPNATTTSRS NDAMSNSTRAMLD 
TAGDYNLTMIEIY NKNTTNTTSGSDD YNRLSNATEQLQE  
 
 
5.3 Acceptor peptides exclusively acted upon by TbSTT3B 
 
TbSTT3A acceptor peptides 
VSNTFNKTGWDVV KFLILNLSMKQGL KLNHTNNSHIIRI 
LMRYNNYTKDPFS KMLTGNLSGFECA AVVKRNTSLVHVL 
LLKLYNFSFVVME TSSALNRTRQKVG RSVSSNTSSMHFS 
GGSKGNVSGGFVD KKCKFNATKAEKS AHLGINVTARTSS 
TVRLVNKTGIYTI AAMIPNATKGTEA KRNALNATAANKV 
VVLWVNISKHPVW KTGNTNTTGSSNS PISFKNLTPSELR 
NLILRNKTEDALT KHCKFNSTKAKEK VKIIENITSAREN 
RIGNVNITGVKGA SYHVVNASLSIGQ KFKLSNASVGAVR 
VSSKSNGTLVSFQ   
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